<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title>International Journal of Molecular Sciences</journal-title>
<abbrev-journal-title>Int. J. Mol. Sci.</abbrev-journal-title>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>Molecular Diversity Preservation International (MDPI)</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3390/ijms14022388</article-id>
<article-id pub-id-type="publisher-id">ijms-14-02388</article-id>
<article-categories>
<subj-group>
<subject>Review</subject></subj-group></article-categories>
<title-group>
<article-title>Parkinson’s Disease: A Complex Interplay of Mitochondrial DNA Alterations and Oxidative Stress</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ciccone</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="af1-ijms-14-02388">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Maiani</surname><given-names>Emiliano</given-names></name><xref ref-type="aff" rid="af1-ijms-14-02388">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Bellusci</surname><given-names>Giovanna</given-names></name><xref ref-type="aff" rid="af1-ijms-14-02388">1</xref></contrib>
<contrib contrib-type="author">
<name><surname>Diederich</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="af2-ijms-14-02388">2</xref><xref ref-type="aff" rid="af3-ijms-14-02388">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>Gonfloni</surname><given-names>Stefania</given-names></name><xref ref-type="aff" rid="af1-ijms-14-02388">1</xref><xref ref-type="aff" rid="af2-ijms-14-02388">2</xref><xref ref-type="corresp" rid="c1-ijms-14-02388">*</xref></contrib></contrib-group>
<aff id="af1-ijms-14-02388">
<label>1</label>Department of Biology, University of Rome “Tor Vergata”, Via della Ricerca Scientifica, 00133 Rome, Italy; E-Mails: <email>sarah.ciccone@gmail.com</email> (S.C.); <email>emiliano.maiani@gmail.com</email> (E.M.); <email>grisolia1982@libero.it</email> (G.B.)</aff>
<aff id="af2-ijms-14-02388">
<label>2</label>Laboratoire de Biologie Moléculaire et Cellulaire du Cancer, Kirchberg Hospital, 9 Rue Edward Steichen, 2540 Luxembourg, Luxembourg; E-Mail: <email>marc.diederich@lbmcc.lu</email></aff>
<aff id="af3-ijms-14-02388">
<label>3</label>College of Pharmacy, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea</aff>
<author-notes>
<corresp id="c1-ijms-14-02388">
<label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>stefania.gonfloni@uniroma2.it</email>; Tel.: +39-06-72594319; Fax: +39-06-2023500.</corresp></author-notes>
<pub-date pub-type="collection">
<year>2013</year></pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>01</month>
<year>2013</year></pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>2388</fpage>
<lpage>2409</lpage>
<history>
<date date-type="received">
<day>05</day>
<month>12</month>
<year>2012</year></date>
<date date-type="rev-recd">
<day>14</day>
<month>01</month>
<year>2013</year></date>
<date date-type="accepted">
<day>21</day>
<month>01</month>
<year>2013</year></date></history>
<permissions>
<copyright-statement>© 2013 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
<p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p></license></permissions>
<abstract>
<p>Parkinson’s disease (PD) is one of the most common age-related neurodegenerative diseases. This pathology causes a significant loss of dopaminergic neurons in the <italic>Substantia Nigra</italic>. Several reports have claimed a role of defective nuclear and mitochondrial DNA repair pathways in PD etiology, in particular, of the Base Excision Repair (BER) system. In addition, recent findings, related to PD progression, indicate that oxidative stress pathways involving c-Abl and GST could also be implicated in this pathology. This review focuses on recently described networks most likely involved in an integrated manner in the course of PD.</p></abstract>
<kwd-group>
<kwd>neurodegenerative diseases</kwd>
<kwd>Parkinson’s disease (PD)</kwd>
<kwd>base excision repair (BER)</kwd>
<kwd>mitochondria</kwd>
<kwd>oxidative stress</kwd>
<kwd>reactive oxidative species (ROS)</kwd>
<kwd>reactive nitrogen species (RNS)</kwd>
<kwd>c-Abl</kwd>
<kwd>reduced glutathione (GSH)</kwd>
<kwd>oxidized glutathione (GSS-)</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>1. Introduction</title>
<p>Over recent years considerable research efforts have focused on age-related neurological disorders. An emerging theme is that many neurodegenerative diseases are most often associated with altered DNA repair mechanisms (<italic>i.e</italic>., Base Excision Repair (BER), Double Strand Break (DSB) and Single Strand Break (SSB) Repair) [<xref ref-type="bibr" rid="b1-ijms-14-02388">1</xref>–<xref ref-type="bibr" rid="b3-ijms-14-02388">3</xref>], mitochondrial defects and oxidative stress [<xref ref-type="bibr" rid="b4-ijms-14-02388">4</xref>].</p>
<p>At first glance, identification of the symptoms at an early stage of neurodegenerative diseases is complex due to their similarity with typical aging [<xref ref-type="bibr" rid="b5-ijms-14-02388">5</xref>]. Moreover, only post-mortem studies can be conducted on patients affected by these pathologies. The complexity of the neurodegenerative diseases is linked to the structural characteristic of the Central Nervous System (CNS), which is composed of brain and spinal cord. In these energy-demanding organs, oxidative damage is very frequent, caused by a sustained oxygen consumption coupled with an inefficient anti-oxidant defense system [<xref ref-type="bibr" rid="b6-ijms-14-02388">6</xref>]. Convincing evidence indicates that oxidative stress, mitochondrial dysfunction and accumulation of mutations in mitochondrial DNA (mtDNA) are hallmarks of neurodegenerative disorder progression [<xref ref-type="bibr" rid="b7-ijms-14-02388">7</xref>] and of aging [<xref ref-type="bibr" rid="b8-ijms-14-02388">8</xref>–<xref ref-type="bibr" rid="b10-ijms-14-02388">10</xref>]. MtDNA is more susceptible to mutations compared to nuclear DNA (nDNA) as it is more exposed to damaging events caused by Reactive Oxygen Species (ROS) generation. Persistent ROS exposure, lack of protection by histone, and reduced DNA repair pathways may lead to harmful point mutations or large-scale rearrangements of mtDNA (reviewed by [<xref ref-type="bibr" rid="b7-ijms-14-02388">7</xref>] and references within). This ends in a progressive accumulation of mtDNA mutations with age, in particular, in tissues with active oxidative metabolism such as brain [<xref ref-type="bibr" rid="b11-ijms-14-02388">11</xref>]. Of note, mtDNA alterations could potentially impact on enzymes involved in ATP production fostering ROS generation. In return, this may cause neuronal cell death, altering both morphology and function of the brain [<xref ref-type="bibr" rid="b6-ijms-14-02388">6</xref>,<xref ref-type="bibr" rid="b12-ijms-14-02388">12</xref>,<xref ref-type="bibr" rid="b13-ijms-14-02388">13</xref>]. In line with this, several reports have correlated accumulation of mtDNA mutations with increased oxidative stress and mitochondrial dysfunction in aging [<xref ref-type="bibr" rid="b8-ijms-14-02388">8</xref>,<xref ref-type="bibr" rid="b9-ijms-14-02388">9</xref>].</p>
<p>Recent reports show that the non-receptor tyrosine kinase c-Abl is involved in neurodegenerative disease progression [<xref ref-type="bibr" rid="b14-ijms-14-02388">14</xref>]. Of note, c-Abl can interact with various proteins implicated either in DNA repair [<xref ref-type="bibr" rid="b15-ijms-14-02388">15</xref>–<xref ref-type="bibr" rid="b17-ijms-14-02388">17</xref>], or in oxidative stress response and even can play a positive role in autophagy, the latter being a process associated with neuroprotection [<xref ref-type="bibr" rid="b18-ijms-14-02388">18</xref>,<xref ref-type="bibr" rid="b19-ijms-14-02388">19</xref>]. In this review, we focus on principal mechanisms that lead to neurodegenerative etiology, starting by the most frequently cited DNA repair pathways (like BER), and also including the emerging role of mitochondrial and oxidative stress. We choose one of the best-known neurodegenerative diseases, Parkinson’s disease (PD), as a paradigm, for assembling each single signaling cascade into an integrated scenario. A deep knowledge of the interplay between mitochondrial alterations and redox signaling may help us to identify the signaling circuitry underlying age-related neurodegenerative diseases. Mitochondrial genome instability and oxidative stress most likely behave as “synthetic lethal interactions” for death decisions in neurons. In turn, this could be exploited to design new combined therapeutic strategies for PD patients.</p></sec>
<sec>
<title>2. DNA Damage and Repair</title>
<p>DNA integrity plays a central role in normal cell growth and the serious consequences deriving from DNA damage are quite intuitive. Persistent DNA damage, in fact, underlies the most important and common human diseases including neurodegenerative diseases and cancer [<xref ref-type="bibr" rid="b20-ijms-14-02388">20</xref>]. DNA damage can be caused by endogenous (like ROS) or exogenous (<italic>i.e.</italic>, ionizing radiation and pesticides) sources. Briefly, the principal types of DNA modifications include (a) apyrimidinic site (loss of a base due to a <italic>N</italic>-glycosil bond cleavage) [<xref ref-type="bibr" rid="b21-ijms-14-02388">21</xref>], (b) deamination (loss of an amino group) [<xref ref-type="bibr" rid="b22-ijms-14-02388">22</xref>], (c) cyclobutane pyrimidine dimers, (one of the principal consequences of UV radiation, in which two pyrimidines situated on the same DNA strand are covalently linked) [<xref ref-type="bibr" rid="b22-ijms-14-02388">22</xref>], (d) trinucleotide repeats expansion (particularly frequent in neurodegenerative diseases) [<xref ref-type="bibr" rid="b23-ijms-14-02388">23</xref>], (e) single strand breaks (SSBs) (a very frequent kind of DNA damage) [<xref ref-type="bibr" rid="b24-ijms-14-02388">24</xref>] or a double strand break (DSB) [<xref ref-type="bibr" rid="b1-ijms-14-02388">1</xref>]. A strand break is a particularly aggressive type of DNA damage eventually leading to replication fork collapse [<xref ref-type="bibr" rid="b25-ijms-14-02388">25</xref>]. DNA strand breaks are the main types of damage present in the neurodegenerative diseases and in aging [<xref ref-type="bibr" rid="b26-ijms-14-02388">26</xref>].</p>
<p>In neurons, prolonged oxygen consumption fosters ROS production. Constant ROS generation may cause DNA damage in the mitochondria thus promoting mitochondrial dysfunctions. Increased ROS production can also cause constant oxidative (DNA) damage in the nucleus. The causal relationship between ROS and mitochondrial (or nuclear) DNA damage strengthen the concept that maintaining ROS at the physiological level is essential for neuronal homeostasis.</p>
<p>When DNA damage occurs, some sensors are activated to induce DNA damage response (DDR). Among them are ATM (ataxia telangiectasia mutated), ATR (ATM and Rad3 related) and DNAPK (DNA dependent protein kinase) kinases belonging to the phosphoinositide-3-kinase-like kinase family. ATM/ATR/DNAPK can lead the cell to DNA repair and cell cycle arrest or apoptosis, if DNA lesions are irreparable [<xref ref-type="bibr" rid="b27-ijms-14-02388">27</xref>,<xref ref-type="bibr" rid="b28-ijms-14-02388">28</xref>]. According to the type of DNA lesions, cells use distinct mechanisms of DNA repair [<xref ref-type="bibr" rid="b29-ijms-14-02388">29</xref>]. Among them, Nucleotide Excision Repair (NER), Base Excision Repair (BER), Mismatch Repair (MMR) and Double Strand Breaks (DSBs) repair, the latter includes two distinct mechanisms based on Homologous Recombination (HR) and Non Homologous End Joining (NHEJ) [<xref ref-type="bibr" rid="b1-ijms-14-02388">1</xref>,<xref ref-type="bibr" rid="b5-ijms-14-02388">5</xref>,<xref ref-type="bibr" rid="b29-ijms-14-02388">29</xref>]. Briefly, DSBs induce a signaling cascade mediated by Rad50-MRE2-NSBI (MRN-complex) and by ATM leading to DNA repair. The choice between HR and NHEJ is tissue specific and depends on the cell cycle phase. HR is active in late S-G2 phases, whereas the NHEJ system acts in G1-early S phase. In the NHEJ pathway, the heterodimer protein KU binds to DSBs, activating DNAPK, which performs end processing. Furthermore, a DNA polymerase promotes repair and synthesis and the pathway ends through the activity of DNA ligase (LIG4/XRCC4). On the contrary, in the HR pathway, the intact chromosome is used like a template to repair the damaged strand. In detail, the DNA ends are processed by the activity of the MRN complex with the help of BRCA1 (Breast Cancer 1), whereas RAD51 monomers invade the damaged strands producing nucleoprotein filaments formation. Further steps lead to the formation of a displacement loop (D-Loop) and DNA repair synthesis mediated by DNA polymerase, with the formation of an intermediate Holliday junction. At the end, DNA ligase LIG1 joins the ends also through the activities of some helicases (Bloom Syndrome RecQ Helicase BLMRecQ, Topoisomerase III alpha TOPO3α and Bloom Syndrome associated protein of 75 kDa BLAP75) that release the Holliday junction [<xref ref-type="bibr" rid="b26-ijms-14-02388">26</xref>,<xref ref-type="bibr" rid="b30-ijms-14-02388">30</xref>].</p>
<p>NER repair is promptly engaged when UV light and polycyclic aromatic hydrocarbons induce alteration of the DNA helix structure. This pathway can be separated into two different cascades namely Global Genome NER (GGNER) and Transcriptional-coupled NER (TCNER). In GGNER, the XPC-HR23B-CEN2 complex (Xeroderma pigmentosum, complementation group C- RAD23 homolog B- centrin, EF-hand protein, 2 complex), with the help of DNA Damage Binding (DDB) complex, senses the damage and recruits the transcription factor TFIIH. In TCNER, damage is recognized by DNA polymerase II with the help of the proteins CSB, CSA (Cockayne Syndrome B Protein and Cockayne Syndrome A Protein) and XAB2 (XPA binding Protein 2). TFIIH is also recruited, and from this point, both GGNER and TCNER proceed similarly. TFIIH uncoils the DNA region in the proximity of the lesion and opens the damaged double helix together with XPB (Xeroderma Pigmentosum complementation group B) and XPD (Xeroderma Pigmentosum complementation group D). Later, the replication protein A (RPA) links the opened DNA to the undamaged strand and endonucleases XPF (Xeroderma Pigmentosum complementation group F) and XPG (Xeroderma Pigmentosum complementation group G) incise the damaged DNA 5′ and 3′ removing the damage and leading to a single strand gap. At this point DNA polymerase δ/κ/ɛ fill the gap and a DNA ligase (LIG1 (Ligase 1 DNA ATP-dependent) or LIG3α-XRCC1 (Ligase III DNA ATP-dependent, X-ray repair complementing defective repair in Chinese hamster cells 1) links the DNA backbone [<xref ref-type="bibr" rid="b31-ijms-14-02388">31</xref>–<xref ref-type="bibr" rid="b33-ijms-14-02388">33</xref>]. In the brain, the principal DNA repair pathway is BER, probably because it is the major pathway used for oxidative damage repair. Monofunctional or bifunctional glycosylases mediate the excision of the damaged base, leading to the formation of an abasic site (AP site). Furthermore, DNA polymerase β and, two enzymes APE1 (AP endonuclease 1) and PNK1 (Polynucleotide Kinase 3′-phosphatase) perform end processing, leading to a 3′-OH and 5′-P termini. At this point, two different kinds of BER can occur: a short-patch BER (SPBER) or, when the numbers of nucleotides replaced is between 2 and 13, a long patch BER (LPBER). In SPBER, DNA repair is conduced by Polβ with the help of XRCC1. Lastly, DNA ligation is made by LIG3. In LPBER, DNA repair and synthesis are performed by Pol δ/ɛ also with the participation of PCNA (Proliferating Cell Nuclear Antigen) and RFC (Replication Factor C), both factors lead to the formation of 5′flap that is removed by FEN1 (flap structure-specific endonuclease 1). The final step is performed by DNA ligase LIG1 [<xref ref-type="bibr" rid="b34-ijms-14-02388">34</xref>,<xref ref-type="bibr" rid="b35-ijms-14-02388">35</xref>].</p>
<p>MMR is another evolutionary conserved mechanism of DNA repair. MMR is implicated in repairing base-base mismatch, or in removing insertion loop arising during replication and recombination [<xref ref-type="bibr" rid="b1-ijms-14-02388">1</xref>,<xref ref-type="bibr" rid="b36-ijms-14-02388">36</xref>,<xref ref-type="bibr" rid="b37-ijms-14-02388">37</xref>]. In this mechanism, MSH (MutS homolog) proteins interact with each other forming specific heterodimers named MUTSα (formed by MSH2 and MSH6 dimers) and MUTSβ (MSH2-MSH3) that recognize, respectively, base mispairing and base deletion on DNA strands. MUTS dimers, after PCNA binding [<xref ref-type="bibr" rid="b38-ijms-14-02388">38</xref>] can recruit MUTL (MutL homolog) dimers, inducing the replacement of damaged region through the action of DNA Polimerase δ and DNA Ligase I [<xref ref-type="bibr" rid="b39-ijms-14-02388">39</xref>]. In humans, MMR is very complex and specific protein-complexes recruitment depends on the location of DNA ends with respect to the mismatch [<xref ref-type="bibr" rid="b40-ijms-14-02388">40</xref>].</p>
<p>Of note ROS damage can induce nucleic acid breakage and also enzyme inactivation, potentially affecting all the components of DNA repair machinery (<xref ref-type="fig" rid="f1-ijms-14-02388">Figure 1</xref>).</p></sec>
<sec>
<title>3. Mitochondrial DNA Alterations in Diseases</title>
<p>As mentioned above, damaged mitochondria play a very important role in the insurgence of several pathologies [<xref ref-type="bibr" rid="b41-ijms-14-02388">41</xref>], including neurodegenerative diseases, due to their involvement in ATP generation [<xref ref-type="bibr" rid="b10-ijms-14-02388">10</xref>]. According to the endosymbiotic theory, mitochondria were bacteria-like organisms embodied by the host cells during the evolution. These subcellular organelles consist of an outer membrane, an intermembrane space and an inner membrane with typical cristae. The inner membrane contains a multi protein complex of enzymes involved in electron transport and ATP generation [<xref ref-type="bibr" rid="b42-ijms-14-02388">42</xref>]. Many groups have focused in recent years on mitochondria, either for the characteristics mentioned above, or because the mtDNA is exclusively transmitted from the mother. Mitochondria are equipped with their own genome consisting of a circular double strand DNA (mtDNA) of 17 kb (see <ext-link xlink:href="http://www.mitomap" ext-link-type="uri">http://www.mitomap</ext-link>). MtDNA encodes only for 13 proteins which are part of the electron transport chain and are involved in the mitochondrial protein synthesis. Mutations affecting mtDNA can cause serious consequences in cells, like neurons, requiring a lot of energy to carry out their functions. Impairment of ATP production is linked to the onset of typical neurological symptoms [<xref ref-type="bibr" rid="b43-ijms-14-02388">43</xref>,<xref ref-type="bibr" rid="b44-ijms-14-02388">44</xref>]. MtDNA is particularly vulnerable to oxidative damage compared to nDNA, due to its proximity to the electron transport chain. More than 150 mtDNA mutations, leading to pathological phenotypes, have been identified up to now. Most of these pathologies can affect the nervous system, endocrine system, skeletal muscle and heart, and also other body organs (<italic>i.e.</italic>, eyes, kidney, brain and liver) [<xref ref-type="bibr" rid="b45-ijms-14-02388">45</xref>,<xref ref-type="bibr" rid="b46-ijms-14-02388">46</xref>]. Lethal mutations are normally eliminated in the mammalian ovary, while milder mutations are transmitted to the germline so ensuring genetic variation in the population [<xref ref-type="bibr" rid="b47-ijms-14-02388">47</xref>]. Some examples of diseases induced by mtDNA mutations are CPEO (Chronic Progressive External Ophthalmoplegia) [<xref ref-type="bibr" rid="b48-ijms-14-02388">48</xref>], KSS (Kearns-Sayre Syndrome) [<xref ref-type="bibr" rid="b49-ijms-14-02388">49</xref>], LHON (Leber’s Hereditary Optic Neuropathy) [<xref ref-type="bibr" rid="b50-ijms-14-02388">50</xref>], MELAS (Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes) [<xref ref-type="bibr" rid="b51-ijms-14-02388">51</xref>] and NARP (Neurogenic Muscle Weakness, Ataxia and Retinitis Pigmentosa) [<xref ref-type="bibr" rid="b52-ijms-14-02388">52</xref>]. Well-known mtDNA mutations identified up to now are: (1) m.3243A &lt; GMTTL, principally responsible of typical symptoms such as diabetes, myopathy, deafness [<xref ref-type="bibr" rid="b53-ijms-14-02388">53</xref>]. (2) m.8344A &lt; GMTTK a mutation leading to the appearance of the myoclonic epilepsy ragged red fibers (MERRF) insurgence [<xref ref-type="bibr" rid="b54-ijms-14-02388">54</xref>]. (3) Single large-scale mtDNA deletions, present in many neurological disorders, often characterized by reduction of life span in the patients affected by these diseases (<italic>i.e.</italic>, Kearns Sayre syndrome, KSS) ([<xref ref-type="bibr" rid="b10-ijms-14-02388">10</xref>] and references within [<xref ref-type="bibr" rid="b42-ijms-14-02388">42</xref>,<xref ref-type="bibr" rid="b55-ijms-14-02388">55</xref>]). Recently, many groups have found that random mutations in mtDNA can affect lifespan in mice and are associated with premature aging [<xref ref-type="bibr" rid="b56-ijms-14-02388">56</xref>,<xref ref-type="bibr" rid="b57-ijms-14-02388">57</xref>]. However, only a limited number of mtDNA mutations occur in natural aging [<xref ref-type="bibr" rid="b58-ijms-14-02388">58</xref>–<xref ref-type="bibr" rid="b63-ijms-14-02388">63</xref>]. Cells adopt several strategies to reduce the effect of mutations occurring into mtDNA. One strategy is mediated by proteases, removing the damaged mitochondrial proteins. Removal of mitochondrial outer membrane proteins is also promoted through ubiquitin-dependent pathways. Another strategy for “mitochondria clearance” is mediated either through the induction of transcription of chaperones, triggered by the presence of unfolded proteins, or eventually through the elimination of entire mitochondrion by autophagy (mitophagy) [<xref ref-type="bibr" rid="b64-ijms-14-02388">64</xref>]. The latter seems to be related to mitochondrial fission and fusion processes. These two mechanisms depend on oxidative phosphorylation and membrane polarization of mitochondria [<xref ref-type="bibr" rid="b65-ijms-14-02388">65</xref>].</p></sec>
<sec>
<title>4. Mitochondrial DNA Damage Repair</title>
<p>In the last two decades many groups have focused on mitochondrial DNA damage repair. Albeit several studies are still in progress, mitochondria seem to share some DNA repair pathways previously described for nDNA. While the presence of NER pathway in mitochondria has not yet been clarified, emerging evidence reveals the existence of mismatch repair, MMR, and base excision repair, BER [<xref ref-type="bibr" rid="b66-ijms-14-02388">66</xref>,<xref ref-type="bibr" rid="b67-ijms-14-02388">67</xref>]. Oxidative DNA damage repair is the major pathway observed in PD and the best-known DNA repair system studied in mitochondria. BER consists of different steps starting from base recognition through DNA glycosylases, while DNA repair is completed through a specific DNA ligase. In the mitochondria the mechanism is the same as well as with the enzymes involved in the process. Firstly, DNA damage is recognized by one of two glycosylases, 8-oxoguanine DNA glycosylase-1 (Ogg1) and Uracil-DNA glycosylase (UNG). Both enzymes are also involved in nDNA damage repair, although, they are expressed as splice isoforms into mitochondria [<xref ref-type="bibr" rid="b1-ijms-14-02388">1</xref>,<xref ref-type="bibr" rid="b68-ijms-14-02388">68</xref>]. Ogg1 is a bifunctional DNA glycosylase that recognizes and cuts 8-hydroxy-guanine. Then, APE1 (the same enzyme implicated in nuclear BER pathway) processes the AP site and leaves DNA Polymerase γ (the only polymerase known in mammalian mitochondria) to insert the correct oligonucleotide (or more oligonucleotides depending on the choice between short-patch BER or long patch BER). Interestingly, recent reports also suggest that APE1 is expressed in mitochondria as a truncated isoform lacking the N-terminal region [<xref ref-type="bibr" rid="b69-ijms-14-02388">69</xref>]. The final step is performed by DNA Ligase III, the latter is a splice variant of the LIG3 gene encoding both for nuclear and mitochondrial enzymes. DNA Ligase III is the only DNA ligase detected in mammalian mitochondria [<xref ref-type="bibr" rid="b67-ijms-14-02388">67</xref>,<xref ref-type="bibr" rid="b70-ijms-14-02388">70</xref>–<xref ref-type="bibr" rid="b72-ijms-14-02388">72</xref>].</p></sec>
<sec>
<title>5. Mitochondrial Defects and Oxidative Stress</title>
<p>Mitochondria play a fundamental role in neurodegenerative disorders [<xref ref-type="bibr" rid="b68-ijms-14-02388">68</xref>] and in aging [<xref ref-type="bibr" rid="b73-ijms-14-02388">73</xref>]. CNS has an urgent need of energy mainly for impulse transmission. For this reason mitochondria are highly enriched in neuronal axons, where the ATP demand is very high. A defect in mitochondrial function, leading to an impaired respiratory chain mechanism, promotes neuronal cell death due to oxidative stress and formation of proteins aggregates (like α-synuclein fibrils in Parkinson’s disease and αβ fibrils in Alzheimer’s disease) [<xref ref-type="bibr" rid="b74-ijms-14-02388">74</xref>].</p>
<p>MtDNA damage impairs mitochondrial energetic capacities, influencing ROS production and eventually leads cells to apoptosis. Both effects are dramatically linked with neurodegenerative disease insurgence and progression [<xref ref-type="bibr" rid="b74-ijms-14-02388">74</xref>,<xref ref-type="bibr" rid="b75-ijms-14-02388">75</xref>]. Mitochondria represent the principal source of ATP in the cell. During ATP production high amounts of ROS (like superoxide anion, O<sub>2</sub>, hydrogen peroxide, H<sub>2</sub>O<sub>2</sub> and hydroxyl radicals, •OH) and RNS (for example nitric oxide, NO and peroxynitrite, ONOO-) can be produced. However, if ROS/RNS are generated within a physiological range, this leads to a signaling pathway inducing transcription of antioxidant enzymes, (such as superoxide dismutase (SOD) that converts superoxide into O<sub>2</sub> into H<sub>2</sub>O<sub>2</sub>, catalase and glutathione peroxidase that reduce H<sub>2</sub>O<sub>2</sub>, glutathione <italic>S</italic>-transferase, heme oxygenase, thioredoxin, glutathione peroxidase <italic>etc.</italic>). Genes encoding these enzymes contain Antioxidant Responsive Element (ARE) activated by redox-sensitive transcription factors (like APE1, Nrf1 and Nrf2 (nuclear factor (erythroid-derived 2)-like 1/2)), which are normally inactivated in the cytosol by specific inhibitors. ROS, RNS and products of lipid oxidation can promote the dissociation of protein inhibitors and transcription factors inducing the synthesis of antioxidant enzymes, phase II detoxification enzymes and stress response proteins [<xref ref-type="bibr" rid="b73-ijms-14-02388">73</xref>,<xref ref-type="bibr" rid="b76-ijms-14-02388">76</xref>–<xref ref-type="bibr" rid="b82-ijms-14-02388">82</xref>]. When the balance between ROS/RNS production and antioxidant enzymes activity is impaired, oxidative damage occurs in the cell producing 8-OHdG (8-hydroxy-2′-deoxyguanosine) and 8-OHG (8-hydroxy-guanosine). The latter are typical markers of oxidative stress observed in the aged human brain in association with synaptic loss and neuronal cell death (<xref ref-type="fig" rid="f2-ijms-14-02388">Figure 2</xref>) [<xref ref-type="bibr" rid="b2-ijms-14-02388">2</xref>].</p>
<p>The mechanisms induced by oxidative stress are very complex and involve several proteins/regulators in addition to the enzymes mentioned above. Among them, a family of non-receptor tyrosine kinases that includes c-Abl (Abl and Abl1) and Abl related genes (Arg and Abl2). c-Abl was early identified as the mammalian homolog of the oncogenic gene product of Abelson murine leukemia virus [<xref ref-type="bibr" rid="b83-ijms-14-02388">83</xref>]. c-Abl is involved in a large number of cellular processes, in DNA repair [<xref ref-type="bibr" rid="b84-ijms-14-02388">84</xref>] and also in neuronal development and in neurodegenerative diseases [<xref ref-type="bibr" rid="b14-ijms-14-02388">14</xref>,<xref ref-type="bibr" rid="b18-ijms-14-02388">18</xref>] (<xref ref-type="fig" rid="f3-ijms-14-02388">Figure 3</xref>). In the brain of Alzheimer’s patients c-Abl co-localizes with granuvacuolar degeneration (GVD) and amyloid β fibrils (αβ fibrils). Moreover, these studies also indicate that oxidative stress induces αβ fibril formation in neuronal cells, while over-expression of c-Abl and p73 leads neurons to apoptosis. Interestingly, the c-Abl/p73 pathway is also described in the cerebellum of mice affected by Niemann-Picktype C, a neurodegenerative disease characterized by neuronal loss due to the excessive uptake of cholesterol [<xref ref-type="bibr" rid="b19-ijms-14-02388">19</xref>,<xref ref-type="bibr" rid="b85-ijms-14-02388">85</xref>–<xref ref-type="bibr" rid="b89-ijms-14-02388">89</xref>].</p>
<p>Further studies indicate a coordinated work between c-Abl and Cdk5 (cyclin-dependent kinase 5) in human neuroblastoma (SHSY5Y) cells. Following oxidative stress, c-Abl phosphorylates Cdk5 on Y15, in return, Cdk5 promotes p53 accumulation and neuronal cell death [<xref ref-type="bibr" rid="b90-ijms-14-02388">90</xref>].</p>
<p>Another important source of oxidative stress is caused by an excessive accumulation of transition metals. In line with this, Fe and Cu are implicated in the progression of several neurodegenerative disorders. Metal storage proteins, like ferritin and cerruloplasmin, are involved in the imbalance of the rate of generation and sequestration of the transition metals. Of note, these proteins are down-regulated in some neurodegenerative diseases such as PD. Moreover, Cu, Fe and Zn, seem to be increased in senile plaques of AD patients, likely inducing oxidative stress in the brain of AD patients (see [<xref ref-type="bibr" rid="b91-ijms-14-02388">91</xref>] and references within). Often oxidative DNA damage is also coupled with a reduced function of DNA repair.</p>
<p>One of the most important antioxidant defense systems relies on GSH detoxification through a non-enzymatic reaction. In the brain, the astrocytes release GSH, providing GSH precursor to neurons. This event regulates GSH metabolism and contributes by improving the neuronal antioxidant defense. Alteration of GSH metabolism has been observed in AD and PD. In particular, GSH reduction can affect either the activity of E1 ubiquitin-ligase and proteasome degradation or JNK-mediated pathway, as a consequence of enhanced oxidative stress [<xref ref-type="bibr" rid="b92-ijms-14-02388">92</xref>–<xref ref-type="bibr" rid="b94-ijms-14-02388">94</xref>].</p>
<p>All these observations, including the role of oxidative stress, of c-Abl and of GSH in the insurgence and progression of neurodegenerative diseases, suggest a possible participation of other enzymes in this mechanism such as Glutathione <italic>S</italic>-transferases (GSTs). These dimeric proteins are mainly involved in oxidative defense system, and have been classified into nine distinct gene families, ubiquitously expressed in the organism. Each monomer contains a ligand site for GSH (G-site) that is highly conserved in all isoforms, and a site for the binding of electrophilic compounds (H-site) that confers to every class of protein a specific substrate affinity. The reaction catalyzed by GSTs enzymes transforms the electrophilic compounds (both endogenous and exogenous) into more hydrophilic ones after their binding with oxidized GSH (GSS-). Then cells can eliminate these conjugates. Moreover, GSTs are only catalytically active as dimers. Under normal conditions, they are present in the cell as a monomeric pool bound to JNK. This implies that GSTs also play an active role in the regulation of JNK-mediated pathway [<xref ref-type="bibr" rid="b95-ijms-14-02388">95</xref>–<xref ref-type="bibr" rid="b98-ijms-14-02388">98</xref>]. In line with our hypothesis, recent reports propose GSTs as a component of signaling pathways that induce neuronal loss in neurodegenerative diseases like PD [<xref ref-type="bibr" rid="b99-ijms-14-02388">99</xref>].</p></sec>
<sec>
<title>6. Parkinson’s Disease</title>
<sec>
<title>6.1. Progression and Typical Symptoms</title>
<p>Here we discuss Parkinson’s disease as a model system for the complex network induced by mitochondrial and nuclear DNA damage and oxidative stress. This disease has obtained in recent years a lot of interest (<xref ref-type="fig" rid="f4-ijms-14-02388">Figure 4</xref>). This interest is partially due to the high occurrence of PD, affecting more than 1% of the population over 65 years old. The major percentage of these cases is identified as sporadic PD and only a small percentage is considered familial PD [<xref ref-type="bibr" rid="b100-ijms-14-02388">100</xref>].</p>
<p>Several causes can lead to sporadic PD insurgence such as the excessive exposure to heavy metals, pesticides or other toxic compounds and oxidative stress [<xref ref-type="bibr" rid="b101-ijms-14-02388">101</xref>–<xref ref-type="bibr" rid="b103-ijms-14-02388">103</xref>]. However, the most frequent causes of PD are mutations of the Parkin gene that encodes for an E3 ubiquitin ligase involved in an ubiquitin-mediated degradation pathway. Mutations in this gene cause an alteration of E3 ubiquitin ligase activity leading to an abnormal protein aggregation, one of the principal clinical features of PD [<xref ref-type="bibr" rid="b104-ijms-14-02388">104</xref>–<xref ref-type="bibr" rid="b107-ijms-14-02388">107</xref>].</p>
<p>Since Parkinson’s disease is characterized by various symptoms linked to different stages of its progression, the identification of this pathology at an early stage is not easy. In fact, the first symptoms are similar to normal aging progression such as rheumatism, fatigue, and depression along with sleep disturbance or loss of elasticity [<xref ref-type="bibr" rid="b108-ijms-14-02388">108</xref>]. Only when the disease is in an advanced stage, most typical symptoms like motor loss and cognitive dysfunction become evident [<xref ref-type="bibr" rid="b100-ijms-14-02388">100</xref>,<xref ref-type="bibr" rid="b107-ijms-14-02388">107</xref>]. Four of the most typical motor symptoms of PD can be considered tremor at rest (the most common symptom of PD regarding principally the hands but also legs, lips jaw and chin and sometimes neck and voice) [<xref ref-type="bibr" rid="b109-ijms-14-02388">109</xref>], rigidity (characterized by a reduction of normal flexion, extension or rotation of a limb) [<xref ref-type="bibr" rid="b110-ijms-14-02388">110</xref>], bradikinesia (reduced capacity to plan and performs movements) [<xref ref-type="bibr" rid="b111-ijms-14-02388">111</xref>], postural instability (loss of postural reflex) [<xref ref-type="bibr" rid="b112-ijms-14-02388">112</xref>]. However, non-motor symptoms can also occur during PD progression; for example sleep disorders, neuropsychiatric disturbances (<italic>i.e.</italic>, dementia and compulsive behavior) and failure of autonomic function [<xref ref-type="bibr" rid="b113-ijms-14-02388">113</xref>]. Disease progression is tightly linked to histopathological features of PD. PD is characterized by a loss of dopaminergic neurons in a specific area of <italic>Substantia Nigra</italic> (SN) accompanied by the formation of Lewy Bodies (LBs) and Lewy Neurites (LNs) that are intracellular inclusions principally constituted by α-synuclein (α-syn), a small protein expressed in SN, cerebellum, hippocampus and neocortex. Although it remains poorly resolved, α-syn can contribute to neural degeneration through a possible mechanism involving mitochondria. Several studies indicate that transgenic mice overexpressing wild type or mutant α-syn show abnormal mitochondrial morphologies [<xref ref-type="bibr" rid="b114-ijms-14-02388">114</xref>]. The <italic>N</italic>-terminal membrane-binding domain of α-syn specifically binds to the membrane of mitochondria rather than to other organelles. In return, α-syn binding causes mitochondrial fragmentation. The amount of α-syn localized into mitochondria of SN neurons increases dramatically in PD [<xref ref-type="bibr" rid="b115-ijms-14-02388">115</xref>]. Some authors have proposed another possible mechanism to enhance α-syn aggregation. This occurs through the interaction of α-syn with mitochondrial complex IV enzyme, cytochrome C oxidase (COX) leading to mitochondrial dysfunction and neuronal degeneration [<xref ref-type="bibr" rid="b116-ijms-14-02388">116</xref>].</p>
<p>The LBs distribution is the base of Braak’s theory, which individuates six stages in PD progression. In the first three stages, there are no evident symptoms; particularly, in the first step where α-syn inclusions are present outside of SN, whereas in the second step LBs and LNs start to be deposed in the medulla oblongata. In stage three; α-syn deposits are present also in midbrain, basal forebrain and in a small part of SN. In stage four, the loss of neurons become evident in SN and in the cerebral cortex. In the last two stages α-syn inclusions invade both SN and neocortex and motor and cognitive dysfunctions occur [<xref ref-type="bibr" rid="b117-ijms-14-02388">117</xref>].</p></sec>
<sec>
<title>6.2. Oxidative Stress and Mitochondrial Mutations/Dysfunction in Parkinson Disease</title>
<p>We have discussed above the role of oxidative stress for PD progression. Several post-mortem studies performed on individuals with Parkinson’s disease have shown an increased level of lipids, proteins and DNA oxidation and a decreased concentration of GSH. In these studies, enrichment of autophagosomes-like structures was observed [<xref ref-type="bibr" rid="b10-ijms-14-02388">10</xref>]. Moreover, a loss of function of genes that encode for proteins involved in autophagy modulation and mitochondrial function has been described in PD. Accordingly, mitochondrial dysfunction seems to be implicated in PD insurgence [<xref ref-type="bibr" rid="b118-ijms-14-02388">118</xref>]. Moreover, it has been indicated that mutations in the kinase PINK1 (PTEN induced putative kinase 1) and in Parkin are both implicated in mitochondrial quality control leading to development of autosomal recessive PD [<xref ref-type="bibr" rid="b106-ijms-14-02388">106</xref>,<xref ref-type="bibr" rid="b119-ijms-14-02388">119</xref>]. PINK1 is present in different districts of the brain, in particular in <italic>substantia nigra</italic>, hippocampus and Purkinje cells of cerebellum. PINK1 has a mitochondrial signal motif in the <italic>N</italic>-terminal domain and a <italic>C</italic>-terminal autoregulatory region. In healthy mitochondria, PINK1 is localized in the inner membrane and is degraded by the protease PARL (Presenilin Associated, Rhomboid-Like) [<xref ref-type="bibr" rid="b120-ijms-14-02388">120</xref>]. Several studies demonstrate that PINK1 is involved in mitochondrial metabolism and dynamics, protein degradation ubiquitin-mediated and oxidative stress [<xref ref-type="bibr" rid="b121-ijms-14-02388">121</xref>,<xref ref-type="bibr" rid="b122-ijms-14-02388">122</xref>]. The role of PINK1 in PD progression is supported by the fact that PINK1 co-localizes with LBs [<xref ref-type="bibr" rid="b123-ijms-14-02388">123</xref>]. Moreover, mice lacking PINK1 have typical symptoms of Parkinson’s disease including mitochondrial impairment of dopaminergic neurons [<xref ref-type="bibr" rid="b124-ijms-14-02388">124</xref>]. Compelling evidence indicates that mutation of PINK1 is one of the principal causes of PD insurgence [<xref ref-type="bibr" rid="b125-ijms-14-02388">125</xref>]. Parkin is another protein implicated in the pathogenesis of different neurodegenerative diseases and, particularly, in PD. Parkin has a <italic>N</italic>-terminal ubiquitin-like domain and a <italic>C</italic>-terminal RING box region with an E3 ubiquitin ligase activity [<xref ref-type="bibr" rid="b126-ijms-14-02388">126</xref>]. Parkin is an important player in controlling the enrichment of protein aggregates. Albeit Parkin can reduce ROS production, the overexpression of mutant Parkin is linked to increased ROS generation. Parkin is associated with mitochondrial DNA. This gives a possible explanation of its protective role against oxidative stress. Post mortem studies performed in subjects affected by PD, demonstrate that Parkin colocalizes with LBs indicating an association with PINK1 and PD progression [<xref ref-type="bibr" rid="b127-ijms-14-02388">127</xref>]. In damaged mitochondria, PINK1 translocates to the outer membrane, where it recruits E3 ligase Parkin from the cytosol. This induces the ubiquitination of outer membrane proteins ending in mitochondrial autophagy (mitophagy). In flies, Parkin accumulation and autophagy induction can cause an enrichment of impaired mitochondria in dopaminergic neurons [<xref ref-type="bibr" rid="b128-ijms-14-02388">128</xref>]. In return, this generates an excessive amount of ROS. A reduced activity of mitochondrial complex I and its inhibitors in <italic>Substantia Nigra</italic> of individuals affected by PD has been recently investigated. Other post-mortem studies performed in <italic>Substantia Nigra pars compacta</italic> (SNpc) of PD patients, indicate an increase of oxidative stress related to dopamine metabolism due to oxidation of dopamine that can generate ROS like H<sub>2</sub>O<sub>2</sub>, which reacts with Fe<sup>2+</sup> forming the reactive •OH by Fenton’s reaction. A consequence of these events is an alteration of the oxidative defense system leading to a reduced concentration of GSH and an increased level of GSSG. Loss of GSH is linked to a reduction of mitochondrial complex I activity in the SNpc, suggesting that decreased GSH is an early event after oxidative stress, ending later on in degeneration of dopaminergic neurons in idiopathic PD [<xref ref-type="bibr" rid="b10-ijms-14-02388">10</xref>,<xref ref-type="bibr" rid="b73-ijms-14-02388">73</xref>,<xref ref-type="bibr" rid="b74-ijms-14-02388">74</xref>,<xref ref-type="bibr" rid="b91-ijms-14-02388">91</xref>].</p>
<p>All the evidence observed in dopaminergic cells and compiled above regarding GSH depletion, mitochondrial complex I activity impairment, and increment of iron level in the context of increased oxidative stress can partially explain the dopaminergic cell death typical in PD. At this purpose, a theory has been postulated according to which in SNpc the level of oxidative stress is low in the physiological condition, but after some insults (for example due to toxic compounds or genetic mutations) the products of oxidative stress are increased. This situation, together with a reduction of GSH level, can create an alteration in the normal protein degradation pathway because of the hurdles for the proteasome to recognize and remove the oxidized proteins. The consequent impairment of protein clearance, generally accompanied by aggregate formation, eventually can lead to cell death [<xref ref-type="bibr" rid="b129-ijms-14-02388">129</xref>]. Moreover, studies conducted in transgenic mice with mito-Pstl (mitochondria-targeted restriction enzyme that induces DSB in the mtDNA, leading to reduced oxidative phosphorylation, OXPHOS) indicate the important role of mtDNA and its role in cell death during PD [<xref ref-type="bibr" rid="b130-ijms-14-02388">130</xref>]. Furthermore, a recent work investigated the relationship between the transcription factor p73 and tyrosine hydroxylase (a fundamental enzyme involved in dopamine synthesis) concluding that p73 can regulate the levels of tyrosine hydroxylase contributing, consequently to protection against PD [<xref ref-type="bibr" rid="b131-ijms-14-02388">131</xref>].</p>
<p>On the other hand, studies conducted <italic>in vitro</italic> and <italic>in vivo</italic> indicate an association between c-Abl and Parkin. Compelling evidence indicates that pharmacological inhibition of c-Abl with STI-571 enhances E3 ligase activity of Parkin. Indeed, c-Abl phosphorylates E3 ligase Parkin on Y143, this induces the accumulation of Aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 (AIMP2) and Fructose-1,6-bisphosphatase 1 (FBP-1). The latter are two toxic substrates of Parkin detected in the striatum. In this manner c-Abl can induce an alternative oxidative stress pathway inhibiting the ubiquitin-mediated pathway by Parkin and promote the accumulation of misfolded protein and toxic substrates (<italic>i.e</italic>., AIMP2 and FBP-1). Moreover, c-Abl activity seems to have a role in PD development also by regulating the activation of PKCδ, as shown in cell culture models of PD. Indeed, PKCδ (Protein kinase C, delta) is activated upon phosphorylation on Y311 by c-Abl, and this modification leads to cell death [<xref ref-type="bibr" rid="b89-ijms-14-02388">89</xref>,<xref ref-type="bibr" rid="b132-ijms-14-02388">132</xref>]. In addition, c-Abl activity can promote neuronal cell death induced by oxidative stress activating the Mammalian ste 20 like kinase (MST1) [<xref ref-type="bibr" rid="b133-ijms-14-02388">133</xref>].</p></sec></sec>
<sec sec-type="conclusions">
<title>7. Conclusions</title>
<p>Parkinson’s disease is the second neuronal disorder, after Alzheimer’s disease (AD), afflicting people over 65 years of age. Despite extensive studies, there are no conclusive remarks regarding this pathology. As mentioned above only post-mortem studies are available for the investigation of PD. Nevertheless, recent reports have shown a very complex network of events underlying the insurgence and progression of PD [<xref ref-type="bibr" rid="b107-ijms-14-02388">107</xref>,<xref ref-type="bibr" rid="b134-ijms-14-02388">134</xref>]. An emerging theme is that persistent oxidative stress is at the basis of PD. This involves the active participation of mitochondria and of several proteins, such as c-Abl or Gluthatione <italic>S</italic>-tranferase in the signaling network underlying neuronal degeneration. Neuronal protection from oxidative stress represents an efficacious strategy against neurodegenerative diseases. While several studies pursuing some combined strategies have been reported, much remains to be done. Mapping the interplay between the different players involved in oxidative stress and DNA damage repair (both in the nucleus and mitochondria), is fundamental to understanding the disease progression and with this, to uncover new opportunities for effective therapeutic strategies.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors wish to thank Gianni Cesareni for support. This work is supported by funds provided by AIRC (Associazione Italiana Ricerca sul Cancro) and Télévie (Luxembourg) to S.G and M.D.: Research in M.D.’s lab is supported by the “Recherche Cancer et Sang”, the “Recherches Scientifiques Luxembourg association”, the “Een Haerz fir kriibskrank Kanner” association, the Action Lions “Vaincre le Cancer” association.</p></ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="G1">AD</term>
<def>
<p>Alzheimer’s Disease</p></def></def-item>
<def-item>
<term id="G2">BER</term>
<def>
<p>Base Excision Repair</p></def></def-item>
<def-item>
<term id="G3">c-Abl</term>
<def>
<p>Abelson tyrosine kinase</p></def></def-item>
<def-item>
<term id="G4">CDK5</term>
<def>
<p>Cyclin-Dependent kinase 5</p></def></def-item>
<def-item>
<term id="G5">DSB</term>
<def>
<p>Double Strand Break</p></def></def-item>
<def-item>
<term id="G6">HR</term>
<def>
<p>Homologous Recombination</p></def></def-item>
<def-item>
<term id="G7">JNK</term>
<def>
<p>c-Jun N-terminal kinase</p></def></def-item>
<def-item>
<term id="G8">LBs</term>
<def>
<p>Lewy Bodies</p></def></def-item>
<def-item>
<term id="G9">LNs</term>
<def>
<p>Lewy Neurites</p></def></def-item>
<def-item>
<term id="G10">mtDNA</term>
<def>
<p>mitochondrial DNA</p></def></def-item>
<def-item>
<term id="G11">nDNA</term>
<def>
<p>nuclear DNA</p></def></def-item>
<def-item>
<term id="G12">NER</term>
<def>
<p>Nucleotide Excision Repair</p></def></def-item>
<def-item>
<term id="G13">NHEJ</term>
<def>
<p>Non Homologous End Joins</p></def></def-item>
<def-item>
<term id="G14">PD</term>
<def>
<p>Parkinson’s Disease</p></def></def-item>
<def-item>
<term id="G15">RNS</term>
<def>
<p>Reactive Nitrogen Species</p></def></def-item>
<def-item>
<term id="G16">ROS</term>
<def>
<p>Reactive Oxidative Species</p></def></def-item>
<def-item>
<term id="G17">SN</term>
<def>
<p>Substantia Nigra</p></def></def-item>
<def-item>
<term id="G18">SSB</term>
<def>
<p>Single Strand Break</p></def></def-item>
<def-item>
<term id="G19">α-syn</term>
<def>
<p>α-synuclein</p></def></def-item></def-list></glossary>
<fn-group><fn id="fn2-ijms-14-02388">
<p><bold>Conflict of Interest</bold></p>
<p>The authors declare no conflict of interest.</p></fn></fn-group>
<ref-list>
<title>References</title>
<ref id="b1-ijms-14-02388"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeppesen</surname><given-names>D.K.</given-names></name><name><surname>Bohr</surname><given-names>V.A.</given-names></name><name><surname>Stevnsner</surname><given-names>T.</given-names></name></person-group><article-title>DNA repair deficiency in neurodegeneration</article-title><source>Prog. Neurobiol</source><year>2011</year><volume>94</volume><fpage>166</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2011.04.013</pub-id><pub-id pub-id-type="pmid">21550379</pub-id></citation></ref>
<ref id="b2-ijms-14-02388"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname><given-names>M.L.</given-names></name><name><surname>Mantha</surname><given-names>A.K.</given-names></name><name><surname>Hazra</surname><given-names>T.K.</given-names></name><name><surname>Bhakat</surname><given-names>K.K.</given-names></name><name><surname>Mitra</surname><given-names>S.</given-names></name><name><surname>Szczesny</surname><given-names>B.</given-names></name></person-group><article-title>Oxidative genome damage and its repair: Implications in aging and neurodegenerative diseases</article-title><source>Mech. Ageing Dev</source><year>2012</year><volume>133</volume><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.mad.2012.01.005</pub-id><pub-id pub-id-type="pmid">22313689</pub-id></citation></ref>
<ref id="b3-ijms-14-02388"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bohgaki</surname><given-names>T.</given-names></name><name><surname>Bohgaki</surname><given-names>M.</given-names></name><name><surname>Hakem</surname><given-names>R.</given-names></name></person-group><article-title>DNA double-strand break signaling and human disorders</article-title><source>Genome Integr</source><year>2010</year><volume>1</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/2041-9414-1-15</pub-id><pub-id pub-id-type="pmid">21054854</pub-id></citation></ref>
<ref id="b4-ijms-14-02388"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dasuri</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Keller</surname><given-names>J.N.</given-names></name></person-group><article-title>Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis</article-title><source>Free Radic. Biol. Med.</source><year>2012</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.09.016</pub-id></citation></ref>
<ref id="b5-ijms-14-02388"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freitas</surname><given-names>A.A.</given-names></name><name><surname>de Magalhaes</surname><given-names>J.P.</given-names></name></person-group><article-title>A review and appraisal of the DNA damage theory of ageing</article-title><source>Mut. Res</source><year>2011</year><volume>728</volume><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.mrrev.2011.05.001</pub-id></citation></ref>
<ref id="b6-ijms-14-02388"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Polidori</surname><given-names>M.C.</given-names></name><name><surname>Griffiths</surname><given-names>H.R.</given-names></name><name><surname>Mariani</surname><given-names>E.</given-names></name><name><surname>Mecocci</surname><given-names>P.</given-names></name></person-group><article-title>Hallmarks of protein oxidative damage in neurodegenerative diseases: Focus on Alzheimer’s disease</article-title><source>Amino Acids</source><year>2007</year><volume>32</volume><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1007/s00726-006-0431-x</pub-id><pub-id pub-id-type="pmid">17273806</pub-id></citation></ref>
<ref id="b7-ijms-14-02388"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>M.H.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name></person-group><article-title>Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease</article-title><source>Free Radic. Biol. Med.</source><year>2012</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.11.014</pub-id></citation></ref>
<ref id="b8-ijms-14-02388"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>R.H.</given-names></name><name><surname>Hou</surname><given-names>J.H.</given-names></name><name><surname>Hsu</surname><given-names>H.S.</given-names></name><name><surname>Wei</surname><given-names>Y.H.</given-names></name></person-group><article-title>Age-dependent respiratory function decline and DNA deletions in human muscle mitochondria</article-title><source>Biochem. Mol. Biol. Int</source><year>1994</year><volume>32</volume><fpage>1009</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">8061617</pub-id></citation></ref>
<ref id="b9-ijms-14-02388"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lezza</surname><given-names>A.M.</given-names></name><name><surname>Boffoli</surname><given-names>D.</given-names></name><name><surname>Scacco</surname><given-names>S.</given-names></name><name><surname>Cantatore</surname><given-names>P.</given-names></name><name><surname>Gadaleta</surname><given-names>M.N.</given-names></name></person-group><article-title>Correlation between mitochondrial DNA 4977-bp deletion and respiratory chain enzyme activities in aging human skeletal muscles</article-title><source>Biochem. Biophys. Res. Commun</source><year>1994</year><volume>205</volume><fpage>772</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1994.2732</pub-id><pub-id pub-id-type="pmid">7999111</pub-id></citation></ref>
<ref id="b10-ijms-14-02388"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lax</surname><given-names>N.Z.</given-names></name><name><surname>Turnbull</surname><given-names>D.M.</given-names></name><name><surname>Reeve</surname><given-names>A.K.</given-names></name></person-group><article-title>Mitochondrial mutations: Newly discovered players in neuronal degeneration</article-title><source>Neuroscientist</source><year>2011</year><volume>17</volume><fpage>645</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1177/1073858411385469</pub-id><pub-id pub-id-type="pmid">22130639</pub-id></citation></ref>
<ref id="b11-ijms-14-02388"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.C.</given-names></name><name><surname>Pang</surname><given-names>C.Y.</given-names></name><name><surname>Hsu</surname><given-names>H.S.</given-names></name><name><surname>Wei</surname><given-names>Y.H.</given-names></name></person-group><article-title>Differential accumulations of 4,977 bp deletion in mitochondrial DNA of various tissues in human ageing</article-title><source>Biochim. Biophys. Acta</source><year>1994</year><volume>1226</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/0925-4439(94)90056-6</pub-id><pub-id pub-id-type="pmid">8155737</pub-id></citation></ref>
<ref id="b12-ijms-14-02388"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>M.</given-names></name><name><surname>Miyata</surname><given-names>R.</given-names></name><name><surname>Tanuma</surname><given-names>N.</given-names></name></person-group><article-title>Oxidative stress in developmental brain disorders</article-title><source>Adv. Exp. Med. Biol</source><year>2012</year><volume>724</volume><fpage>278</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">22411250</pub-id></citation></ref>
<ref id="b13-ijms-14-02388"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mecocci</surname><given-names>P.</given-names></name></person-group><article-title>Oxidative stress in mild cognitive impairment and Alzheimer disease: A continuum</article-title><source>J. Alzheimer’s Dis</source><year>2004</year><volume>6</volume><fpage>159</fpage><lpage>163</lpage></citation></ref>
<ref id="b14-ijms-14-02388"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schlatterer</surname><given-names>S.D.</given-names></name><name><surname>Acker</surname><given-names>C.M.</given-names></name><name><surname>Davies</surname><given-names>P.</given-names></name></person-group><article-title>c-Abl in neurodegenerative disease</article-title><source>J. Mol. Neurosci</source><year>2011</year><volume>45</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1007/s12031-011-9588-1</pub-id><pub-id pub-id-type="pmid">21728062</pub-id></citation></ref>
<ref id="b15-ijms-14-02388"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonfloni</surname><given-names>S.</given-names></name></person-group><article-title>DNA damage stress response in germ cells: Role of c-Abl and clinical implications</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>6193</fpage><lpage>6202</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.410</pub-id><pub-id pub-id-type="pmid">20818431</pub-id></citation></ref>
<ref id="b16-ijms-14-02388"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colicelli</surname><given-names>J</given-names></name></person-group><article-title>ABL tyrosine kinases: Evolution of function, regulation, and specificity</article-title><source>Sci. Signal.</source><year>2010</year><volume>3</volume><fpage>re6</fpage><pub-id pub-id-type="doi">10.1126/scisignal.3139re6</pub-id><pub-id pub-id-type="pmid">20841568</pub-id></citation></ref>
<ref id="b17-ijms-14-02388"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shaul</surname><given-names>Y.</given-names></name><name><surname>Ben-Yehoyada</surname><given-names>M.</given-names></name></person-group><article-title>Role of c-Abl in the DNA damage stress response</article-title><source>Cell Res</source><year>2005</year><volume>15</volume><fpage>33</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/sj.cr.7290261</pub-id><pub-id pub-id-type="pmid">15686624</pub-id></citation></ref>
<ref id="b18-ijms-14-02388"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonfloni</surname><given-names>S.</given-names></name><name><surname>Maiani</surname><given-names>E.</given-names></name><name><surname>Di Bartolomeo</surname><given-names>C.</given-names></name><name><surname>Diederich</surname><given-names>M.</given-names></name><name><surname>Cesareni</surname><given-names>G.</given-names></name></person-group><article-title>Oxidative stress, DNA damage, and c-Abl signaling: At the crossroad in neurodegenerative diseases?</article-title><source>Int. J. Cell Biol</source><year>2012</year><volume>2012</volume><fpage>683097</fpage><pub-id pub-id-type="pmid">22761618</pub-id></citation></ref>
<ref id="b19-ijms-14-02388"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schlatterer</surname><given-names>S.D.</given-names></name><name><surname>Tremblay</surname><given-names>M.A.</given-names></name><name><surname>Acker</surname><given-names>C.M.</given-names></name><name><surname>Davies</surname><given-names>P.</given-names></name></person-group><article-title>Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain</article-title><source>J. Alzheimer’s Dis</source><year>2011</year><volume>25</volume><fpage>119</fpage><lpage>133</lpage></citation></ref>
<ref id="b20-ijms-14-02388"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devine</surname><given-names>M.J.</given-names></name><name><surname>Plun-Favreau</surname><given-names>H.</given-names></name><name><surname>Wood</surname><given-names>N.W.</given-names></name></person-group><article-title>Parkinson’s disease and cancer: Two wars, one front</article-title><source>Nat. Rev. Cancer</source><year>2011</year><volume>11</volume><fpage>812</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/nrc3150</pub-id><pub-id pub-id-type="pmid">22020207</pub-id></citation></ref>
<ref id="b21-ijms-14-02388"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>J.</given-names></name><name><surname>Swenberg</surname><given-names>J.A.</given-names></name></person-group><article-title>Endogenous apurinic/apyrimidinic sites in genomic DNA of mammalian tissues</article-title><source>Cancer Res.</source><year>1999</year><volume>59</volume><fpage>2522</fpage><lpage>2526</lpage><pub-id pub-id-type="pmid">10363965</pub-id></citation></ref>
<ref id="b22-ijms-14-02388"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedberg</surname><given-names>E.C.</given-names></name><name><surname>Aguilera</surname><given-names>A.</given-names></name><name><surname>Gellert</surname><given-names>M.</given-names></name><name><surname>Hanawalt</surname><given-names>P.C.</given-names></name><name><surname>Hays</surname><given-names>J.B.</given-names></name><name><surname>Lehmann</surname><given-names>A.R.</given-names></name><name><surname>Lindahl</surname><given-names>T.</given-names></name><name><surname>Lowndes</surname><given-names>N.</given-names></name><name><surname>Sarasin</surname><given-names>A.</given-names></name><name><surname>Wood</surname><given-names>R.D.</given-names></name></person-group><article-title>DNA repair: From molecular mechanism to human disease</article-title><source>DNA Repair</source><year>2006</year><volume>5</volume><fpage>986</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2006.05.005</pub-id><pub-id pub-id-type="pmid">16955546</pub-id></citation></ref>
<ref id="b23-ijms-14-02388"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wilson</surname><given-names>S.H.</given-names></name></person-group><article-title>DNA base excision repair: A mechanism of trinucleotide repeat expansion</article-title><source>Trends Biochem. Sci</source><year>2012</year><volume>37</volume><fpage>162</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2011.12.002</pub-id><pub-id pub-id-type="pmid">22285516</pub-id></citation></ref>
<ref id="b24-ijms-14-02388"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caldecott</surname><given-names>K.W.</given-names></name></person-group><article-title>Single-strand break repair and genetic disease</article-title><source>Nat. Rev. Genet</source><year>2008</year><volume>9</volume><fpage>619</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">18626472</pub-id></citation></ref>
<ref id="b25-ijms-14-02388"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cahill</surname><given-names>D.</given-names></name><name><surname>Connor</surname><given-names>B.</given-names></name><name><surname>Carney</surname><given-names>J.P.</given-names></name></person-group><article-title>Mechanisms of eukaryotic DNA double strand break repair</article-title><source>Front. Biosci</source><year>2006</year><volume>11</volume><fpage>1958</fpage><lpage>1976</lpage><pub-id pub-id-type="doi">10.2741/1938</pub-id><pub-id pub-id-type="pmid">16368571</pub-id></citation></ref>
<ref id="b26-ijms-14-02388"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Engels</surname><given-names>W.R.</given-names></name><name><surname>Johnson-Schlitz</surname><given-names>D.</given-names></name><name><surname>Flores</surname><given-names>C.</given-names></name><name><surname>White</surname><given-names>L.</given-names></name><name><surname>Preston</surname><given-names>C.R.</given-names></name></person-group><article-title>A third link connecting aging with double strand break repair</article-title><source>Cell Cycle</source><year>2007</year><volume>6</volume><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.4161/cc.6.2.3758</pub-id><pub-id pub-id-type="pmid">17245130</pub-id></citation></ref>
<ref id="b27-ijms-14-02388"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B.P.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Asaithamby</surname><given-names>A.</given-names></name></person-group><article-title>New insights into the roles of ATM and DNA-PKcs in the cellular response to oxidative stress</article-title><source>Cancer Lett</source><year>2012</year><volume>327</volume><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.12.004</pub-id><pub-id pub-id-type="pmid">22155347</pub-id></citation></ref>
<ref id="b28-ijms-14-02388"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korwek</surname><given-names>Z.</given-names></name><name><surname>Sewastianik</surname><given-names>T.</given-names></name><name><surname>Bielak-Zmijewska</surname><given-names>A.</given-names></name><name><surname>Mosieniak</surname><given-names>G.</given-names></name><name><surname>Alster</surname><given-names>O.</given-names></name><name><surname>Moreno-Villaneuva</surname><given-names>M.</given-names></name><name><surname>Burkle</surname><given-names>A.</given-names></name><name><surname>Sikora</surname><given-names>E.</given-names></name></person-group><article-title>Inhibition of ATM blocks the etoposide-induced DNA damage response and apoptosis of resting human T cells</article-title><source>DNA Repair</source><year>2012</year><volume>11</volume><fpage>864</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2012.08.006</pub-id><pub-id pub-id-type="pmid">23058634</pub-id></citation></ref>
<ref id="b29-ijms-14-02388"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>K.</given-names></name><name><surname>Nowsheen</surname><given-names>S.</given-names></name><name><surname>Pantelias</surname><given-names>G.</given-names></name><name><surname>Iliakis</surname><given-names>G.</given-names></name><name><surname>Gorgoulis</surname><given-names>V.G.</given-names></name><name><surname>Georgakilas</surname><given-names>A.G.</given-names></name></person-group><article-title>Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy</article-title><source>Pharmacol. Ther</source><year>2012</year><volume>133</volume><fpage>334</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2011.11.010</pub-id><pub-id pub-id-type="pmid">22197993</pub-id></citation></ref>
<ref id="b30-ijms-14-02388"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vyjayanti</surname><given-names>V.N.</given-names></name><name><surname>Rao</surname><given-names>K.S.</given-names></name></person-group><article-title>DNA double strand break repair in brain: Reduced NHEJ activity in aging rat neurons</article-title><source>Neurosci. Lett</source><year>2006</year><volume>393</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2005.09.053</pub-id><pub-id pub-id-type="pmid">16226837</pub-id></citation></ref>
<ref id="b31-ijms-14-02388"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niedernhofer</surname><given-names>L.J.</given-names></name></person-group><article-title>Tissue-specific accelerated aging in nucleotide excision repair deficiency. Mechanisms of ageing and development</article-title><source>Mech. Ageing Dev</source><year>2008</year><volume>129</volume><fpage>408</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/j.mad.2008.04.010</pub-id><pub-id pub-id-type="pmid">18538374</pub-id></citation></ref>
<ref id="b32-ijms-14-02388"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fousteri</surname><given-names>M.</given-names></name><name><surname>Mullenders</surname><given-names>L.H.</given-names></name></person-group><article-title>Transcription-coupled nucleotide excision repair in mammalian cells: Molecular mechanisms and biological effects</article-title><source>Cell Res</source><year>2008</year><volume>18</volume><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.6</pub-id><pub-id pub-id-type="pmid">18166977</pub-id></citation></ref>
<ref id="b33-ijms-14-02388"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shuck</surname><given-names>S.C.</given-names></name><name><surname>Short</surname><given-names>E.A.</given-names></name><name><surname>Turchi</surname><given-names>J.J.</given-names></name></person-group><article-title>Eukaryotic nucleotide excision repair: From understanding mechanisms to influencing biology</article-title><source>Cell Res</source><year>2008</year><volume>18</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1038/cr.2008.2</pub-id><pub-id pub-id-type="pmid">18166981</pub-id></citation></ref>
<ref id="b34-ijms-14-02388"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fishel</surname><given-names>M.L.</given-names></name><name><surname>Vasko</surname><given-names>M.R.</given-names></name><name><surname>Kelley</surname><given-names>M.R.</given-names></name></person-group><article-title>DNA repair in neurons: So if they don’t divide what’s to repair?</article-title><source>Mut. Res</source><year>2007</year><volume>614</volume><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2006.06.007</pub-id></citation></ref>
<ref id="b35-ijms-14-02388"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maynard</surname><given-names>S.</given-names></name><name><surname>Schurman</surname><given-names>S.H.</given-names></name><name><surname>Harboe</surname><given-names>C.</given-names></name><name><surname>de Souza-Pinto</surname><given-names>N.C.</given-names></name><name><surname>Bohr</surname><given-names>V.A.</given-names></name></person-group><article-title>Base excision repair of oxidative DNA damage and association with cancer and aging</article-title><source>Carcinogenesis</source><year>2009</year><volume>30</volume><fpage>2</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">18978338</pub-id></citation></ref>
<ref id="b36-ijms-14-02388"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiricny</surname><given-names>J.</given-names></name></person-group><article-title>The multifaceted mismatch-repair system</article-title><source>Nat. Rev. Mol. Cell Biol</source><year>2006</year><volume>7</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">16612326</pub-id></citation></ref>
<ref id="b37-ijms-14-02388"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunkel</surname><given-names>T.A.</given-names></name><name><surname>Erie</surname><given-names>D.A.</given-names></name></person-group><article-title>DNA mismatch repair</article-title><source>Ann. Rev. Biochem.</source><year>2005</year><volume>74</volume><fpage>681</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.74.082803.133243</pub-id><pub-id pub-id-type="pmid">15952900</pub-id></citation></ref>
<ref id="b38-ijms-14-02388"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Hashiguchi</surname><given-names>K.</given-names></name><name><surname>Hoshi</surname><given-names>M.</given-names></name><name><surname>Lan</surname><given-names>L.</given-names></name><name><surname>Yasui</surname><given-names>A.</given-names></name></person-group><article-title>Recruitment of mismatch repair proteins to the site of DNA damage in human cells</article-title><source>J. Cell Sci</source><year>2008</year><volume>121</volume><fpage>3146</fpage><lpage>3154</lpage><pub-id pub-id-type="doi">10.1242/jcs.026393</pub-id><pub-id pub-id-type="pmid">18765568</pub-id></citation></ref>
<ref id="b39-ijms-14-02388"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conde-Perezprina</surname><given-names>J.C.</given-names></name><name><surname>Leon-Galvan</surname><given-names>M.A.</given-names></name><name><surname>Konigsberg</surname><given-names>M.</given-names></name></person-group><article-title>DNA mismatch repair system: Repercussions in cellular homeostasis and relationship with aging</article-title><source>Oxid. Med. Cell. Longevity</source><year>2012</year><volume>2012</volume><fpage>728430</fpage></citation></ref>
<ref id="b40-ijms-14-02388"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lujan</surname><given-names>S.A.</given-names></name><name><surname>Williams</surname><given-names>J.S.</given-names></name><name><surname>Pursell</surname><given-names>Z.F.</given-names></name><name><surname>Abdulovic-Cui</surname><given-names>A.A.</given-names></name><name><surname>Clark</surname><given-names>A.B.</given-names></name><name><surname>Nick McElhinny</surname><given-names>S.A.</given-names></name><name><surname>Kunkel</surname><given-names>T.A.</given-names></name></person-group><article-title>Mismatch repair balances leading and lagging strand DNA replication fidelity</article-title><source>PLoS Genet</source><year>2012</year><volume>8</volume><fpage>e1003016</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1003016</pub-id><pub-id pub-id-type="pmid">23071460</pub-id></citation></ref>
<ref id="b41-ijms-14-02388"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lenaz</surname><given-names>G.</given-names></name></person-group><article-title>The mitochondrial production of reactive oxygen species: Mechanisms and implications in human pathology</article-title><source>IUBMB Life</source><year>2001</year><volume>52</volume><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1080/15216540152845957</pub-id><pub-id pub-id-type="pmid">11798028</pub-id></citation></ref>
<ref id="b42-ijms-14-02388"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Osellame</surname><given-names>L.D.</given-names></name><name><surname>Blacker</surname><given-names>T.S.</given-names></name><name><surname>Duchen</surname><given-names>M.R.</given-names></name></person-group><article-title>Cellular and molecular mechanisms of mitochondrial function</article-title><source>Best Pract. Res. Clin. Endocrinol. Metab</source><year>2012</year><volume>26</volume><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2012.05.003</pub-id><pub-id pub-id-type="pmid">23168274</pub-id></citation></ref>
<ref id="b43-ijms-14-02388"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorolla</surname><given-names>M.A.</given-names></name><name><surname>Rodriguez-Colman</surname><given-names>M.J.</given-names></name><name><surname>Vall-llaura</surname><given-names>N.</given-names></name><name><surname>Tamarit</surname><given-names>J.</given-names></name><name><surname>Ros</surname><given-names>J.</given-names></name><name><surname>Cabiscol</surname><given-names>E.</given-names></name></person-group><article-title>Protein oxidation in Huntington disease</article-title><source>Biofactors</source><year>2012</year><volume>38</volume><fpage>173</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1002/biof.1013</pub-id><pub-id pub-id-type="pmid">22473822</pub-id></citation></ref>
<ref id="b44-ijms-14-02388"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zadori</surname><given-names>D.</given-names></name><name><surname>Klivenyi</surname><given-names>P.</given-names></name><name><surname>Szalardy</surname><given-names>L.</given-names></name><name><surname>Fulop</surname><given-names>F.</given-names></name><name><surname>Toldi</surname><given-names>J.</given-names></name><name><surname>Vecsei</surname><given-names>L.</given-names></name></person-group><article-title>Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: Novel therapeutic strategies for neurodegenerative disorders</article-title><source>J. Neurol. Sci</source><year>2012</year><volume>322</volume><fpage>187</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2012.06.004</pub-id><pub-id pub-id-type="pmid">22749004</pub-id></citation></ref>
<ref id="b45-ijms-14-02388"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gasparre</surname><given-names>G.</given-names></name><name><surname>Romeo</surname><given-names>G.</given-names></name><name><surname>Rugolo</surname><given-names>M.</given-names></name><name><surname>Porcelli</surname><given-names>A.M.</given-names></name></person-group><article-title>Learning from oncocytic tumors: Why choose inefficient mitochondria?</article-title><source>Biochim. Biophys. Acta</source><year>2011</year><volume>1807</volume><fpage>633</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2010.08.006</pub-id><pub-id pub-id-type="pmid">20732299</pub-id></citation></ref>
<ref id="b46-ijms-14-02388"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karbownik-Lewi Ska</surname><given-names>M.G.</given-names></name><name><surname>St Pniak</surname><given-names>J.</given-names></name><name><surname>Lewi Ski</surname><given-names>A.</given-names></name></person-group><article-title>High level of oxidized nucleosides in thyroid mitochondrial DNA; damaging effects of Fenton reaction substrates</article-title><source>Thyroid Res</source><year>2012</year><volume>5</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/1756-6614-5-24</pub-id><pub-id pub-id-type="pmid">23267669</pub-id></citation></ref>
<ref id="b47-ijms-14-02388"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>D.C.</given-names></name></person-group><article-title>Mitochondrial DNA mutations in disease and aging</article-title><source>Environ. Mol. Mutagen</source><year>2010</year><volume>51</volume><fpage>440</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">20544884</pub-id></citation></ref>
<ref id="b48-ijms-14-02388"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Hong</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name></person-group><article-title>Chronic progressive external ophthalmoplegia coexistent with motor neuron disease in a patient with a novel large-scale mitochondrial DNA deletion</article-title><source>Clin. Neurol. Neurosurg.</source><year>2012</year><pub-id pub-id-type="doi">10.1016/j.clineuro.2012.11.011</pub-id></citation></ref>
<ref id="b49-ijms-14-02388"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comte</surname><given-names>C.</given-names></name><name><surname>Tonin</surname><given-names>Y.</given-names></name><name><surname>Heckel-Mager</surname><given-names>A.M.</given-names></name><name><surname>Boucheham</surname><given-names>A.</given-names></name><name><surname>Smirnov</surname><given-names>A.</given-names></name><name><surname>Aure</surname><given-names>K.</given-names></name><name><surname>Lornbes</surname><given-names>A.</given-names></name><name><surname>Martin</surname><given-names>R.P.</given-names></name><name><surname>Entelis</surname><given-names>N.</given-names></name><name><surname>Tarassov</surname><given-names>I.</given-names></name></person-group><article-title>Mitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associated with Kearns Sayre Syndrome</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><fpage>418</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1093/nar/gks965</pub-id><pub-id pub-id-type="pmid">23087375</pub-id></citation></ref>
<ref id="b50-ijms-14-02388"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caporali</surname><given-names>L.</given-names></name><name><surname>Ghelli</surname><given-names>A.M.</given-names></name><name><surname>Iommarini</surname><given-names>L.</given-names></name><name><surname>Maresca</surname><given-names>A.</given-names></name><name><surname>Valentino</surname><given-names>M.L.</given-names></name><name><surname>La Morgia</surname><given-names>C.</given-names></name><name><surname>Liguori</surname><given-names>R.</given-names></name><name><surname>Zanna</surname><given-names>C.</given-names></name><name><surname>Barboni</surname><given-names>P.</given-names></name><name><surname>De Nardo</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Cybrid studies establish the causal link between the mtDNA m.3890G&gt;A/MT-ND1 mutation and optic atrophy with bilateral brainstem lesions</article-title><source>Biochim. Biophys. Acta</source><year>2012</year><volume>1832</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">23246842</pub-id></citation></ref>
<ref id="b51-ijms-14-02388"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tschampa</surname><given-names>H.J.</given-names></name><name><surname>Urbach</surname><given-names>H.</given-names></name><name><surname>Greschus</surname><given-names>S.</given-names></name><name><surname>Kunz</surname><given-names>W.S.</given-names></name><name><surname>Kornblum</surname><given-names>C</given-names></name></person-group><article-title>Neuroimaging characteristics in mitochondrial encephalopathies associated with the m.3243A&gt;G MTTL1 mutation</article-title><source>J. Neurol.</source><year>2012</year><pub-id pub-id-type="doi">10.1007/s00415-012-6763-4</pub-id></citation></ref>
<ref id="b52-ijms-14-02388"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Gallardo</surname><given-names>E.</given-names></name><name><surname>Solano</surname><given-names>A.</given-names></name><name><surname>Herrero-Martin</surname><given-names>M.D.</given-names></name><name><surname>Martinez-Romero</surname><given-names>I.</given-names></name><name><surname>Castano-Perez</surname><given-names>M.D.</given-names></name><name><surname>Andreu</surname><given-names>A.L.</given-names></name><name><surname>Herrera</surname><given-names>A.</given-names></name><name><surname>López-Pérez</surname><given-names>M.J.</given-names></name><name><surname>Ruiz-Pesini</surname><given-names>E.</given-names></name><name><surname>Montoya</surname><given-names>J.</given-names></name></person-group><article-title>NARP syndrome in a patient harbouring an insertion in the MT-ATP6 gene that results in a truncated protein</article-title><source>J. Med. Genet</source><year>2009</year><volume>46</volume><fpage>64</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">19124644</pub-id></citation></ref>
<ref id="b53-ijms-14-02388"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>Y.</given-names></name><name><surname>Nonaka</surname><given-names>I.</given-names></name><name><surname>Horai</surname><given-names>S.</given-names></name></person-group><article-title>A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies</article-title><source>Nature</source><year>1990</year><volume>348</volume><fpage>651</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1038/348651a0</pub-id><pub-id pub-id-type="pmid">2102678</pub-id></citation></ref>
<ref id="b54-ijms-14-02388"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shoffner</surname><given-names>J.M.</given-names></name><name><surname>Lott</surname><given-names>M.T.</given-names></name><name><surname>Lezza</surname><given-names>A.M.</given-names></name><name><surname>Seibel</surname><given-names>P.</given-names></name><name><surname>Ballinger</surname><given-names>S.W.</given-names></name><name><surname>Wallace</surname><given-names>D.C.</given-names></name></person-group><article-title>Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation</article-title><source>Cell</source><year>1990</year><volume>61</volume><fpage>931</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90059-N</pub-id><pub-id pub-id-type="pmid">2112427</pub-id></citation></ref>
<ref id="b55-ijms-14-02388"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Monden</surname><given-names>Y.</given-names></name><name><surname>Mori</surname><given-names>M.</given-names></name><name><surname>Kuwajima</surname><given-names>M.</given-names></name><name><surname>Goto</surname><given-names>T.</given-names></name><name><surname>Yamagata</surname><given-names>T.</given-names></name><name><surname>Momoi</surname><given-names>M.Y.</given-names></name></person-group><article-title>Late-onset Leigh syndrome with myoclonic epilepsy with ragged-red fibers</article-title><source>Brain Dev.</source><year>2012</year><pub-id pub-id-type="doi">10.1016/j.braindev.2012.08.006</pub-id></citation></ref>
<ref id="b56-ijms-14-02388"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barja</surname><given-names>G.</given-names></name><name><surname>Herrero</surname><given-names>A.</given-names></name></person-group><article-title>Oxidative damage to mitochondrial DNA is inversely related to maximum life span in the heart and brain of mammals</article-title><source>FASEB J</source><year>2000</year><volume>14</volume><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">10657987</pub-id></citation></ref>
<ref id="b57-ijms-14-02388"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mecocci</surname><given-names>P.</given-names></name><name><surname>MacGarvey</surname><given-names>U.</given-names></name><name><surname>Kaufman</surname><given-names>A.E.</given-names></name><name><surname>Koontz</surname><given-names>D.</given-names></name><name><surname>Shoffner</surname><given-names>J.M.</given-names></name><name><surname>Wallace</surname><given-names>D.C.</given-names></name><name><surname>Beal</surname><given-names>M.F.</given-names></name></person-group><article-title>Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain</article-title><source>Ann. Neurol</source><year>1993</year><volume>34</volume><fpage>609</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1002/ana.410340416</pub-id><pub-id pub-id-type="pmid">8215249</pub-id></citation></ref>
<ref id="b58-ijms-14-02388"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y.H.</given-names></name><name><surname>Lee</surname><given-names>H.C.</given-names></name></person-group><article-title>Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging</article-title><source>Exp. Biol. Med. (Maywood)</source><year>2002</year><volume>227</volume><fpage>671</fpage><lpage>682</lpage></citation></ref>
<ref id="b59-ijms-14-02388"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>M.T.</given-names></name><name><surname>Beal</surname><given-names>M.F.</given-names></name></person-group><article-title>Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases</article-title><source>Nature</source><year>2006</year><volume>443</volume><fpage>787</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1038/nature05292</pub-id><pub-id pub-id-type="pmid">17051205</pub-id></citation></ref>
<ref id="b60-ijms-14-02388"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>D.S.</given-names></name><name><surname>Beal</surname><given-names>M.F.</given-names></name></person-group><article-title>Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease</article-title><source>J. Neural Transm. Suppl</source><year>2000</year><volume>59</volume><fpage>133</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">10961426</pub-id></citation></ref>
<ref id="b61-ijms-14-02388"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Weindruch</surname><given-names>R.</given-names></name><name><surname>Prolla</surname><given-names>T.A.</given-names></name></person-group><article-title>Gene-expression profile of the ageing brain in mice</article-title><source>Nat. Genet</source><year>2000</year><volume>25</volume><fpage>294</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1038/77046</pub-id><pub-id pub-id-type="pmid">10888876</pub-id></citation></ref>
<ref id="b62-ijms-14-02388"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greaves</surname><given-names>L.C.</given-names></name><name><surname>Elson</surname><given-names>J.L.</given-names></name><name><surname>Nooteboom</surname><given-names>M.</given-names></name><name><surname>Grady</surname><given-names>J.P.</given-names></name><name><surname>Taylor</surname><given-names>G.A.</given-names></name><name><surname>Taylor</surname><given-names>R.W.</given-names></name><name><surname>Mathers</surname><given-names>J.C.</given-names></name><name><surname>Kirkwood</surname><given-names>T.B.</given-names></name><name><surname>Turnbull</surname><given-names>D.M.</given-names></name></person-group><article-title>Comparison of mitochondrial mutation spectra in ageing human colonic epithelium and disease: Absence of evidence for purifying selection in somatic mitochondrial DNA point mutations</article-title><source>PLoS Genet</source><year>2012</year><volume>8</volume><fpage>e1003082</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1003082</pub-id><pub-id pub-id-type="pmid">23166522</pub-id></citation></ref>
<ref id="b63-ijms-14-02388"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.C.</given-names></name><name><surname>Chang</surname><given-names>C.M.</given-names></name><name><surname>Chi</surname><given-names>C.W.</given-names></name></person-group><article-title>Somatic mutations of mitochondrial DNA in aging and cancer progression</article-title><source>Ageing Res. Rev</source><year>2010</year><volume>9</volume><fpage>S47</fpage><lpage>S58</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2010.08.009</pub-id><pub-id pub-id-type="pmid">20816876</pub-id></citation></ref>
<ref id="b64-ijms-14-02388"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ashrafi</surname><given-names>G.</given-names></name><name><surname>Schwarz</surname><given-names>T.L.</given-names></name></person-group><article-title>The pathways of mitophagy for quality control and clearance of mitochondria</article-title><source>Cell Death Differ</source><year>2012</year><volume>20</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">22743996</pub-id></citation></ref>
<ref id="b65-ijms-14-02388"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Youle</surname><given-names>R.J.</given-names></name><name><surname>van der Bliek</surname><given-names>A.M.</given-names></name></person-group><article-title>Mitochondrial fission, fusion, and stress</article-title><source>Science</source><year>2012</year><volume>337</volume><fpage>1062</fpage><lpage>1065</lpage><pub-id pub-id-type="doi">10.1126/science.1219855</pub-id><pub-id pub-id-type="pmid">22936770</pub-id></citation></ref>
<ref id="b66-ijms-14-02388"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Souza-Pinto</surname><given-names>N.C.</given-names></name><name><surname>Mason</surname><given-names>P.A.</given-names></name><name><surname>Hashiguchi</surname><given-names>K.</given-names></name><name><surname>Weissman</surname><given-names>L.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Guay</surname><given-names>D.</given-names></name><name><surname>Lebel</surname><given-names>M.</given-names></name><name><surname>Stevnsner</surname><given-names>T.V.</given-names></name><name><surname>Rasmussen</surname><given-names>L.J.</given-names></name><name><surname>Bohr</surname><given-names>V.A.</given-names></name></person-group><article-title>Novel DNA mismatch-repair activity involving YB-1 in human mitochondria</article-title><source>DNA Repair</source><year>2009</year><volume>8</volume><fpage>704</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2009.01.021</pub-id><pub-id pub-id-type="pmid">19272840</pub-id></citation></ref>
<ref id="b67-ijms-14-02388"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gredilla</surname><given-names>R.</given-names></name></person-group><article-title>DNA damage and base excision repair in mitochondria and their role in aging</article-title><source>J. Aging Res</source><year>2010</year><volume>2011</volume><fpage>257093</fpage><pub-id pub-id-type="pmid">21234332</pub-id></citation></ref>
<ref id="b68-ijms-14-02388"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname><given-names>K.H.</given-names></name><name><surname>Moldestad</surname><given-names>O.</given-names></name><name><surname>Eide</surname><given-names>L.</given-names></name><name><surname>Carlsen</surname><given-names>H.</given-names></name><name><surname>Nesse</surname><given-names>G.</given-names></name><name><surname>Storm</surname><given-names>J.F.</given-names></name><name><surname>Mansuy</surname><given-names>I.M.</given-names></name><name><surname>Bergersen</surname><given-names>L.H.</given-names></name><name><surname>Klungland</surname><given-names>A.</given-names></name></person-group><article-title>Mitochondrial DNA toxicity in forebrain neurons causes apoptosis, neurodegeneration, and impaired behavior</article-title><source>Mol. Cell. Biol</source><year>2010</year><volume>30</volume><fpage>1357</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1128/MCB.01149-09</pub-id><pub-id pub-id-type="pmid">20065039</pub-id></citation></ref>
<ref id="b69-ijms-14-02388"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>S.</given-names></name><name><surname>Izumi</surname><given-names>T.</given-names></name><name><surname>Boldogh</surname><given-names>I.</given-names></name><name><surname>Bhakat</surname><given-names>K.K.</given-names></name><name><surname>Chattopadhyay</surname><given-names>R.</given-names></name><name><surname>Szczesny</surname><given-names>B.</given-names></name></person-group><article-title>Intracellular trafficking and regulation of mammalian AP-endonuclease 1 (APE1), an essential DNA repair protein</article-title><source>DNA Repair</source><year>2007</year><volume>6</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2006.10.010</pub-id><pub-id pub-id-type="pmid">17166779</pub-id></citation></ref>
<ref id="b70-ijms-14-02388"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L.J.</given-names></name></person-group><article-title>Biology of mitochondria in neurodegenerative diseases</article-title><source>Prog. Mol. Biol. Transl. Sci</source><year>2012</year><volume>107</volume><fpage>355</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">22482456</pub-id></citation></ref>
<ref id="b71-ijms-14-02388"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsen</surname><given-names>N.B.</given-names></name><name><surname>Rasmussen</surname><given-names>M.</given-names></name><name><surname>Rasmussen</surname><given-names>L.J.</given-names></name></person-group><article-title>Nuclear and mitochondrial DNA repair: Similar pathways?</article-title><source>Mitochondrion</source><year>2005</year><volume>5</volume><fpage>89</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.mito.2005.02.002</pub-id><pub-id pub-id-type="pmid">16050976</pub-id></citation></ref>
<ref id="b72-ijms-14-02388"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gredilla</surname><given-names>R.</given-names></name><name><surname>Bohr</surname><given-names>V.A.</given-names></name><name><surname>Stevnsner</surname><given-names>T.</given-names></name></person-group><article-title>Mitochondrial DNA repair and association with aging—An update</article-title><source>Exp. Gerontol</source><year>2010</year><volume>45</volume><fpage>478</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.exger.2010.01.017</pub-id><pub-id pub-id-type="pmid">20096766</pub-id></citation></ref>
<ref id="b73-ijms-14-02388"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S.</given-names></name><name><surname>Munshi</surname><given-names>S.</given-names></name><name><surname>Banerjee</surname><given-names>K.</given-names></name><name><surname>Thakurta</surname><given-names>I.G.</given-names></name><name><surname>Sinha</surname><given-names>M.</given-names></name><name><surname>Bagh</surname><given-names>M.B.</given-names></name></person-group><article-title>Mitochondrial dysfunction during brain aging: Role of oxidative stress and modulation by antioxidant supplementation</article-title><source>Aging Dis</source><year>2011</year><volume>2</volume><fpage>242</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">22396876</pub-id></citation></ref>
<ref id="b74-ijms-14-02388"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Federico</surname><given-names>A.</given-names></name><name><surname>Cardaioli</surname><given-names>E.</given-names></name><name><surname>Da Pozzo</surname><given-names>P.</given-names></name><name><surname>Formichi</surname><given-names>P.</given-names></name><name><surname>Gallus</surname><given-names>G.N.</given-names></name><name><surname>Radi</surname><given-names>E.</given-names></name></person-group><article-title>Mitochondria, oxidative stress and neurodegeneration</article-title><source>J. Neurol. Sci</source><year>2012</year><volume>322</volume><fpage>254</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2012.05.030</pub-id><pub-id pub-id-type="pmid">22669122</pub-id></citation></ref>
<ref id="b75-ijms-14-02388"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filosto</surname><given-names>M.</given-names></name><name><surname>Scarpelli</surname><given-names>M.</given-names></name><name><surname>Cotelli</surname><given-names>M.S.</given-names></name><name><surname>Vielmi</surname><given-names>V.</given-names></name><name><surname>Todeschini</surname><given-names>A.</given-names></name><name><surname>Gregorelli</surname><given-names>V.</given-names></name><name><surname>Tonin</surname><given-names>P.</given-names></name><name><surname>Tomelleri</surname><given-names>G.</given-names></name><name><surname>Padovani</surname><given-names>A.</given-names></name></person-group><article-title>The role of mitochondria in neurodegenerative diseases</article-title><source>J. Neurol</source><year>2011</year><volume>258</volume><fpage>1763</fpage><lpage>1774</lpage><pub-id pub-id-type="doi">10.1007/s00415-011-6104-z</pub-id><pub-id pub-id-type="pmid">21604203</pub-id></citation></ref>
<ref id="b76-ijms-14-02388"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loeb</surname><given-names>L.A.</given-names></name><name><surname>Wallace</surname><given-names>D.C.</given-names></name><name><surname>Martin</surname><given-names>G.M.</given-names></name></person-group><article-title>The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>18769</fpage><lpage>18770</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509776102</pub-id><pub-id pub-id-type="pmid">16365283</pub-id></citation></ref>
<ref id="b77-ijms-14-02388"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>D.G.</given-names></name></person-group><article-title>Oxidative stress and energy crises in neuronal dysfunction</article-title><source>Ann. N. Y. Acad. Sci</source><year>2008</year><volume>1147</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1196/annals.1427.002</pub-id><pub-id pub-id-type="pmid">19076430</pub-id></citation></ref>
<ref id="b78-ijms-14-02388"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.C.</given-names></name><name><surname>Wei</surname><given-names>Y.H.</given-names></name></person-group><article-title>Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress</article-title><source>Int. J. Biochem. Cell Biol</source><year>2005</year><volume>37</volume><fpage>822</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2004.09.010</pub-id><pub-id pub-id-type="pmid">15694841</pub-id></citation></ref>
<ref id="b79-ijms-14-02388"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scarpulla</surname><given-names>R.C.</given-names></name></person-group><article-title>Transcriptional paradigms in mammalian mitochondrial biogenesis and function</article-title><source>Physiol. Rev</source><year>2008</year><volume>88</volume><fpage>611</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1152/physrev.00025.2007</pub-id><pub-id pub-id-type="pmid">18391175</pub-id></citation></ref>
<ref id="b80-ijms-14-02388"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Siow</surname><given-names>R.C.</given-names></name><name><surname>Mann</surname><given-names>G.E.</given-names></name></person-group><article-title>Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: A role for mitochondria and the nuclear factor-E2-related factor 2-Kelch-like ECH-associated protein 1 defense pathway</article-title><source>Antioxid. Redox Signal</source><year>2011</year><volume>14</volume><fpage>469</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1089/ars.2010.3283</pub-id><pub-id pub-id-type="pmid">20524845</pub-id></citation></ref>
<ref id="b81-ijms-14-02388"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kensler</surname><given-names>T.W.</given-names></name><name><surname>Wakabayashi</surname><given-names>N.</given-names></name><name><surname>Biswal</surname><given-names>S.</given-names></name></person-group><article-title>Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway</article-title><source>Ann. Rev. Pharmacol. Toxicol</source><year>2007</year><volume>47</volume><fpage>89</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.46.120604.141046</pub-id></citation></ref>
<ref id="b82-ijms-14-02388"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niture</surname><given-names>S.K.</given-names></name><name><surname>Kaspar</surname><given-names>J.W.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Jaiswal</surname><given-names>A.K.</given-names></name></person-group><article-title>Nrf2 signaling and cell survival</article-title><source>Toxicol. Appl. Pharmacol</source><year>2010</year><volume>244</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2009.06.009</pub-id><pub-id pub-id-type="pmid">19538984</pub-id></citation></ref>
<ref id="b83-ijms-14-02388"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozanne</surname><given-names>B.</given-names></name><name><surname>Wheeler</surname><given-names>T.</given-names></name><name><surname>Zack</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>G.</given-names></name><name><surname>Dale</surname><given-names>B.</given-names></name></person-group><article-title>Transforming gene of a human leukaemia cell is unrelated to the expressed tumour virus related gene of the cell</article-title><source>Nature</source><year>1982</year><volume>299</volume><fpage>744</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1038/299744a0</pub-id><pub-id pub-id-type="pmid">7121605</pub-id></citation></ref>
<ref id="b84-ijms-14-02388"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maiani</surname><given-names>E.</given-names></name><name><surname>Diederich</surname><given-names>M.</given-names></name><name><surname>Gonfloni</surname><given-names>S.</given-names></name></person-group><article-title>DNA damage response: The emerging role of c-Abl as a regulatory switch?</article-title><source>Biochem. Pharmacol</source><year>2011</year><volume>82</volume><fpage>1269</fpage><lpage>1266</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2011.07.001</pub-id><pub-id pub-id-type="pmid">21763684</pub-id></citation></ref>
<ref id="b85-ijms-14-02388"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herrup</surname><given-names>K.</given-names></name></person-group><article-title>Reimagining Alzheimer’s disease—An age-based hypothesis</article-title><source>J. Neurosci</source><year>2010</year><volume>30</volume><fpage>16755</fpage><lpage>16762</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4521-10.2010</pub-id><pub-id pub-id-type="pmid">21159946</pub-id></citation></ref>
<ref id="b86-ijms-14-02388"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname><given-names>Z.</given-names></name><name><surname>Caltagarone</surname><given-names>J.</given-names></name><name><surname>Bowser</surname><given-names>R.</given-names></name></person-group><article-title>Altered subcellular distribution of c-Abl in Alzheimer’s disease</article-title><source>J. Alzheimer’s Dis</source><year>2009</year><volume>17</volume><fpage>409</fpage><lpage>422</lpage></citation></ref>
<ref id="b87-ijms-14-02388"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kharbanda</surname><given-names>S.</given-names></name><name><surname>Ren</surname><given-names>R.</given-names></name><name><surname>Pandey</surname><given-names>P.</given-names></name><name><surname>Shafman</surname><given-names>T.D.</given-names></name><name><surname>Feller</surname><given-names>S.M.</given-names></name><name><surname>Weichselbaum</surname><given-names>R.R.</given-names></name><name><surname>Kufe</surname><given-names>D.W.</given-names></name></person-group><article-title>Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents</article-title><source>Nature</source><year>1995</year><volume>376</volume><fpage>785</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/376785a0</pub-id><pub-id pub-id-type="pmid">7651539</pub-id></citation></ref>
<ref id="b88-ijms-14-02388"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cancino</surname><given-names>G.I.</given-names></name><name><surname>Toledo</surname><given-names>E.M.</given-names></name><name><surname>Leal</surname><given-names>N.R.</given-names></name><name><surname>Hernandez</surname><given-names>D.E.</given-names></name><name><surname>Yévenes</surname><given-names>L.F.</given-names></name><name><surname>Inestrosa</surname><given-names>N.C.</given-names></name><name><surname>Alvarez</surname><given-names>A.R.</given-names></name></person-group><article-title>STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer’s beta-amyloid deposits</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>2425</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.1093/brain/awn125</pub-id><pub-id pub-id-type="pmid">18559370</pub-id></citation></ref>
<ref id="b89-ijms-14-02388"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Shin</surname><given-names>J.H.</given-names></name><name><surname>Karuppagounder</surname><given-names>S.S.</given-names></name><name><surname>Gadad</surname><given-names>B.S.</given-names></name><name><surname>Koleske</surname><given-names>A.J.</given-names></name><name><surname>Pletnikova</surname><given-names>O.</given-names></name><name><surname>Troncoso</surname><given-names>J.C.</given-names></name><name><surname>Dawson</surname><given-names>V.L.</given-names></name><name><surname>Dawson</surname><given-names>T.M.</given-names></name></person-group><article-title>Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>16691</fpage><lpage>16696</lpage><pub-id pub-id-type="doi">10.1073/pnas.1006083107</pub-id><pub-id pub-id-type="pmid">20823226</pub-id></citation></ref>
<ref id="b90-ijms-14-02388"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cancino</surname><given-names>G.I.</given-names></name><name><surname>Perez de Arce</surname><given-names>K.</given-names></name><name><surname>Castro</surname><given-names>P.U.</given-names></name><name><surname>Toledo</surname><given-names>E.M.</given-names></name><name><surname>von Bernhardi</surname><given-names>R.</given-names></name><name><surname>Alvarez</surname><given-names>A.R.</given-names></name></person-group><article-title>c-Abl tyrosine kinase modulates tau pathology and Cdk5 phosphorylation in AD transgenic mice</article-title><source>Neurobiol. Aging</source><year>2011</year><volume>32</volume><fpage>1249</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.07.007</pub-id><pub-id pub-id-type="pmid">19700222</pub-id></citation></ref>
<ref id="b91-ijms-14-02388"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cacciatore</surname><given-names>I.</given-names></name><name><surname>Baldassarre</surname><given-names>L.</given-names></name><name><surname>Fornasari</surname><given-names>E.</given-names></name><name><surname>Mollica</surname><given-names>A.</given-names></name><name><surname>Pinnen</surname><given-names>F.</given-names></name></person-group><article-title>Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems</article-title><source>Oxid. Med. Cell. Longevity</source><year>2012</year><volume>2012</volume><fpage>240146</fpage></citation></ref>
<ref id="b92-ijms-14-02388"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bains</surname><given-names>J.S.</given-names></name><name><surname>Shaw</surname><given-names>C.A.</given-names></name></person-group><article-title>Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death</article-title><source>Brain Res. Brain Res. Rev</source><year>1997</year><volume>25</volume><fpage>335</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/S0165-0173(97)00045-3</pub-id><pub-id pub-id-type="pmid">9495562</pub-id></citation></ref>
<ref id="b93-ijms-14-02388"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>M.</given-names></name><name><surname>Tereshchenko</surname><given-names>Y.</given-names></name><name><surname>Zhevtsova</surname><given-names>Z.</given-names></name><name><surname>Taschenberger</surname><given-names>G.</given-names></name><name><surname>Bahr</surname><given-names>M.</given-names></name><name><surname>Kugler</surname><given-names>S.</given-names></name></person-group><article-title>Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons</article-title><source>Acta Neuropathol</source><year>2011</year><volume>121</volume><fpage>475</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1007/s00401-010-0791-x</pub-id><pub-id pub-id-type="pmid">21191602</pub-id></citation></ref>
<ref id="b94-ijms-14-02388"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>J.</given-names></name><name><surname>Kanski</surname><given-names>J.</given-names></name><name><surname>Varadarajan</surname><given-names>S.</given-names></name><name><surname>Tsoras</surname><given-names>M.</given-names></name><name><surname>Butterfield</surname><given-names>D.A.</given-names></name></person-group><article-title>Elevation of brain glutathione by gamma-glutamylcysteine ethyl ester protects against peroxynitrite-induced oxidative stress</article-title><source>J. Neurosci. Res</source><year>2002</year><volume>68</volume><fpage>776</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1002/jnr.10266</pub-id><pub-id pub-id-type="pmid">12111838</pub-id></citation></ref>
<ref id="b95-ijms-14-02388"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>J.D.</given-names></name><name><surname>Flanagan</surname><given-names>J.U.</given-names></name><name><surname>Jowsey</surname><given-names>I.R.</given-names></name></person-group><article-title>Glutathione transferases</article-title><source>Ann. Rev. pharmacol. Toxicol</source><year>2005</year><volume>45</volume><fpage>51</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.095857</pub-id></citation></ref>
<ref id="b96-ijms-14-02388"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilce</surname><given-names>M.C.</given-names></name><name><surname>Parker</surname><given-names>M.W.</given-names></name></person-group><article-title>Structure and function of glutathione <italic>S</italic>-transferases</article-title><source>Biochim. Biophys. Acta</source><year>1994</year><volume>1205</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/0167-4838(94)90086-8</pub-id><pub-id pub-id-type="pmid">8142473</pub-id></citation></ref>
<ref id="b97-ijms-14-02388"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nuccetelli</surname><given-names>M.</given-names></name><name><surname>Mazzetti</surname><given-names>A.P.</given-names></name><name><surname>Rossjohn</surname><given-names>J.</given-names></name><name><surname>Parker</surname><given-names>M.W.</given-names></name><name><surname>Board</surname><given-names>P.</given-names></name><name><surname>Caccuri</surname><given-names>A.M.</given-names></name><name><surname>Federici</surname><given-names>G.</given-names></name><name><surname>Ricci</surname><given-names>G.</given-names></name><name><surname>Lo Bello</surname><given-names>M.</given-names></name></person-group><article-title>Shifting substrate specificity of human glutathione transferase (from class Pi to class alpha) by a single point mutation</article-title><source>Biochem. Biophys. Res. Commun</source><year>1998</year><volume>252</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1998.9575</pub-id><pub-id pub-id-type="pmid">9813167</pub-id></citation></ref>
<ref id="b98-ijms-14-02388"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabrini</surname><given-names>R.</given-names></name><name><surname>de Luca</surname><given-names>A.</given-names></name><name><surname>Stella</surname><given-names>L.</given-names></name><name><surname>Mei</surname><given-names>G.</given-names></name><name><surname>Orioni</surname><given-names>B.</given-names></name><name><surname>Ciccone</surname><given-names>S.</given-names></name><name><surname>Federici</surname><given-names>G.</given-names></name><name><surname>Lo Bello</surname><given-names>M.</given-names></name><name><surname>Ricci</surname><given-names>G.</given-names></name></person-group><article-title>Monomer-dimer equilibrium in glutathione transferases: A critical re-examination</article-title><source>Biochemistry</source><year>2009</year><volume>48</volume><fpage>10473</fpage><lpage>10482</lpage><pub-id pub-id-type="doi">10.1021/bi901238t</pub-id><pub-id pub-id-type="pmid">19795889</pub-id></citation></ref>
<ref id="b99-ijms-14-02388"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Liou</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Weng</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name><name><surname>Zigmond</surname><given-names>M.J.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>GST P1, a novel downstream regulator of LRRK2, G2019S-induced neuronal cell death</article-title><source>Front. Biosci</source><year>2012</year><volume>4</volume><fpage>2365</fpage><lpage>2377</lpage></citation></ref>
<ref id="b100-ijms-14-02388"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname><given-names>J.</given-names></name></person-group><article-title>Parkinson’s disease: Clinical features and diagnosis</article-title><source>J. Neurol. Neurosurg. Psychiatry</source><year>2008</year><volume>79</volume><fpage>368</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2007.131045</pub-id><pub-id pub-id-type="pmid">18344392</pub-id></citation></ref>
<ref id="b101-ijms-14-02388"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Przedborski</surname><given-names>S.</given-names></name></person-group><article-title>Oxidative stress in Parkinson’s disease: A mechanism of pathogenic and therapeutic significance</article-title><source>Ann. N. Y. Acad. Sci</source><year>2008</year><volume>1147</volume><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1196/annals.1427.023</pub-id><pub-id pub-id-type="pmid">19076434</pub-id></citation></ref>
<ref id="b102-ijms-14-02388"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chinta</surname><given-names>S.J.</given-names></name><name><surname>Andersen</surname><given-names>J.K.</given-names></name></person-group><article-title>Redox imbalance in Parkinson’s disease</article-title><source>Biochim. Biophys. Acta</source><year>2008</year><volume>1780</volume><fpage>1362</fpage><lpage>1367</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2008.02.005</pub-id><pub-id pub-id-type="pmid">18358848</pub-id></citation></ref>
<ref id="b103-ijms-14-02388"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>E.C.</given-names></name><name><surname>Brandel</surname><given-names>J.P.</given-names></name><name><surname>Galle</surname><given-names>P.</given-names></name><name><surname>Javoy-Agid</surname><given-names>F.</given-names></name><name><surname>Agid</surname><given-names>Y.</given-names></name></person-group><article-title>Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: An X-ray microanalysis</article-title><source>J. Neurochem</source><year>1991</year><volume>56</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1991.tb08170.x</pub-id><pub-id pub-id-type="pmid">1988548</pub-id></citation></ref>
<ref id="b104-ijms-14-02388"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>K.K.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Lim</surname><given-names>K.L.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Ross</surname><given-names>C.A.</given-names></name><name><surname>Dawson</surname><given-names>V.L.</given-names></name><name><surname>Dawson</surname><given-names>T.M.</given-names></name></person-group><article-title>Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: Implications for Lewy-body formation in Parkinson disease</article-title><source>Nat. Med</source><year>2001</year><volume>7</volume><fpage>1144</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1038/nm1001-1144</pub-id><pub-id pub-id-type="pmid">11590439</pub-id></citation></ref>
<ref id="b105-ijms-14-02388"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>K.K.</given-names></name><name><surname>Thomas</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Pletnikova</surname><given-names>O.</given-names></name><name><surname>Troncoso</surname><given-names>J.C.</given-names></name><name><surname>Marsh</surname><given-names>L.</given-names></name><name><surname>Dawson</surname><given-names>V.L.</given-names></name><name><surname>Dawson</surname><given-names>T.M.</given-names></name></person-group><article-title><italic>S</italic>-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1328</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1126/science.1093891</pub-id><pub-id pub-id-type="pmid">15105460</pub-id></citation></ref>
<ref id="b106-ijms-14-02388"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitada</surname><given-names>T.</given-names></name><name><surname>Asakawa</surname><given-names>S.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name><name><surname>Matsumine</surname><given-names>H.</given-names></name><name><surname>Yamamura</surname><given-names>Y.</given-names></name><name><surname>Minoshima</surname><given-names>S.</given-names></name><name><surname>Yokochi</surname><given-names>M.</given-names></name><name><surname>Mizuno</surname><given-names>Y.</given-names></name><name><surname>Shimizu</surname><given-names>N.</given-names></name></person-group><article-title>Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>605</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1038/33416</pub-id><pub-id pub-id-type="pmid">9560156</pub-id></citation></ref>
<ref id="b107-ijms-14-02388"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>D.J.</given-names></name><name><surname>West</surname><given-names>A.B.</given-names></name><name><surname>Dawson</surname><given-names>V.L.</given-names></name><name><surname>Dawson</surname><given-names>T.M.</given-names></name></person-group><article-title>Molecular pathophysiology of Parkinson’s disease</article-title><source>Ann. Rev. Neurosci</source><year>2005</year><volume>28</volume><fpage>57</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1146/annurev.neuro.28.061604.135718</pub-id><pub-id pub-id-type="pmid">16022590</pub-id></citation></ref>
<ref id="b108-ijms-14-02388"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blalock</surname><given-names>E.M.</given-names></name><name><surname>Chen</surname><given-names>K.C.</given-names></name><name><surname>Sharrow</surname><given-names>K.</given-names></name><name><surname>Herman</surname><given-names>J.P.</given-names></name><name><surname>Porter</surname><given-names>N.M.</given-names></name><name><surname>Foster</surname><given-names>T.C.</given-names></name><name><surname>Landfield</surname><given-names>P.W.</given-names></name></person-group><article-title>Gene microarrays in hippocampal aging: Statistical profiling identifies novel processes correlated with cognitive impairment</article-title><source>J. Neurosci</source><year>2003</year><volume>23</volume><fpage>3807</fpage><lpage>3819</lpage><pub-id pub-id-type="pmid">12736351</pub-id></citation></ref>
<ref id="b109-ijms-14-02388"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>L.M.</given-names></name><name><surname>Singer</surname><given-names>C.</given-names></name><name><surname>Bean</surname><given-names>J.A.</given-names></name><name><surname>Weiner</surname><given-names>W.J.</given-names></name></person-group><article-title>Internal tremor in patients with Parkinson’s disease</article-title><source>Mov. Disord</source><year>1996</year><volume>11</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/mds.870110103</pub-id><pub-id pub-id-type="pmid">8771060</pub-id></citation></ref>
<ref id="b110-ijms-14-02388"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villarejo</surname><given-names>A.</given-names></name><name><surname>Camacho</surname><given-names>A.</given-names></name><name><surname>García-Ramos</surname><given-names>R.</given-names></name><name><surname>Moreno</surname><given-names>T.</given-names></name><name><surname>Penas</surname><given-names>M.</given-names></name><name><surname>Juntas</surname><given-names>R.</given-names></name><name><surname>Ruiz</surname><given-names>J.</given-names></name></person-group><article-title>Cholinergic-dopaminergic imbalance in Pisa syndrome</article-title><source>Clin. Neuropharmacol</source><year>2003</year><volume>26</volume><fpage>119</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1097/00002826-200305000-00004</pub-id><pub-id pub-id-type="pmid">12782913</pub-id></citation></ref>
<ref id="b111-ijms-14-02388"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berardelli</surname><given-names>A.</given-names></name><name><surname>Rothwell</surname><given-names>J.C.</given-names></name><name><surname>Thompson</surname><given-names>P.D.</given-names></name><name><surname>Hallett</surname><given-names>M.</given-names></name></person-group><article-title>Pathophysiology of bradykinesia in Parkinson’s disease</article-title><source>Brain</source><year>2001</year><volume>124</volume><fpage>2131</fpage><lpage>2146</lpage><pub-id pub-id-type="doi">10.1093/brain/124.11.2131</pub-id><pub-id pub-id-type="pmid">11673316</pub-id></citation></ref>
<ref id="b112-ijms-14-02388"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stefani</surname><given-names>A.</given-names></name><name><surname>Lozano</surname><given-names>A.M.</given-names></name><name><surname>Peppe</surname><given-names>A.</given-names></name><name><surname>Stanzione</surname><given-names>P.</given-names></name><name><surname>Galati</surname><given-names>S.</given-names></name><name><surname>Tropepi</surname><given-names>D.</given-names></name><name><surname>Pierantozzi</surname><given-names>M.</given-names></name><name><surname>Brusa</surname><given-names>L.</given-names></name><name><surname>Scarnati</surname><given-names>E.</given-names></name><name><surname>Mazzone</surname><given-names>P.</given-names></name></person-group><article-title>Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>1596</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1093/brain/awl346</pub-id><pub-id pub-id-type="pmid">17251240</pub-id></citation></ref>
<ref id="b113-ijms-14-02388"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zesiewicz</surname><given-names>T.A.</given-names></name><name><surname>Sullivan</surname><given-names>K.L.</given-names></name><name><surname>Hauser</surname><given-names>R.A.</given-names></name></person-group><article-title>Nonmotor symptoms of Parkinson’s disease</article-title><source>Expert Rev. Neurother</source><year>2006</year><volume>6</volume><fpage>1811</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1586/14737175.6.12.1811</pub-id><pub-id pub-id-type="pmid">17181428</pub-id></citation></ref>
<ref id="b114-ijms-14-02388"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name></person-group><article-title>Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e36377</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0036377</pub-id><pub-id pub-id-type="pmid">22558453</pub-id></citation></ref>
<ref id="b115-ijms-14-02388"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Nemani</surname><given-names>V.M.</given-names></name><name><surname>Azarbal</surname><given-names>F.</given-names></name><name><surname>Skibinski</surname><given-names>G.</given-names></name><name><surname>Levy</surname><given-names>J.M.</given-names></name><name><surname>Egami</surname><given-names>K.</given-names></name><name><surname>Munishkina</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Gardner</surname><given-names>B.</given-names></name><name><surname>Wakabayashi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>20710</fpage><lpage>20726</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.213538</pub-id><pub-id pub-id-type="pmid">21489994</pub-id></citation></ref>
<ref id="b116-ijms-14-02388"><label>116</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elkon</surname><given-names>H.</given-names></name><name><surname>Don</surname><given-names>J.</given-names></name><name><surname>Melamed</surname><given-names>E.</given-names></name><name><surname>Ziv</surname><given-names>I.</given-names></name><name><surname>Shirvan</surname><given-names>A.</given-names></name><name><surname>Offen</surname><given-names>D.</given-names></name></person-group><article-title>Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase</article-title><source>J. Mol. Neurosci</source><year>2002</year><volume>18</volume><fpage>229</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1385/JMN:18:3:229</pub-id><pub-id pub-id-type="pmid">12059041</pub-id></citation></ref>
<ref id="b117-ijms-14-02388"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H.</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Pathoanatomy of Parkinson’s disease</article-title><source>J. Neurol.</source><year>2000</year><volume>247</volume><fpage>II3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/PL00007758</pub-id><pub-id pub-id-type="pmid">10991663</pub-id></citation></ref>
<ref id="b118-ijms-14-02388"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arduino</surname><given-names>D.M.</given-names></name><name><surname>Esteves</surname><given-names>A.R.</given-names></name><name><surname>Cardoso</surname><given-names>S.M.</given-names></name></person-group><article-title>Mitochondria drive autophagy pathology via microtubule disassembly: A new hypothesis for Parkinson disease</article-title><source>Autophagy</source><year>2012</year><volume>9</volume><fpage>112</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">23075854</pub-id></citation></ref>
<ref id="b119-ijms-14-02388"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pienaar</surname><given-names>I.S.</given-names></name><name><surname>Chinnery</surname><given-names>P.F.</given-names></name></person-group><article-title>Existing and emerging mitochondrial-targeting therapies for altering Parkinson’s disease severity and progression</article-title><source>Pharmacol. Ther.</source><year>2012</year><pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.08.010</pub-id></citation></ref>
<ref id="b120-ijms-14-02388"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greene</surname><given-names>A.W.</given-names></name><name><surname>Grenier</surname><given-names>K.</given-names></name><name><surname>Aguileta</surname><given-names>M.A.</given-names></name><name><surname>Muise</surname><given-names>S.</given-names></name><name><surname>Farazifard</surname><given-names>R.</given-names></name><name><surname>Haque</surname><given-names>M.E.</given-names></name><name><surname>McBride</surname><given-names>H.M.</given-names></name><name><surname>Park</surname><given-names>D.S.</given-names></name><name><surname>Fon</surname><given-names>E.A.</given-names></name></person-group><article-title>Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment</article-title><source>EMBO Rep</source><year>2012</year><volume>13</volume><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/embor.2012.14</pub-id><pub-id pub-id-type="pmid">22354088</pub-id></citation></ref>
<ref id="b121-ijms-14-02388"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pridgeon</surname><given-names>J.W.</given-names></name><name><surname>Olzmann</surname><given-names>J.A.</given-names></name><name><surname>Chin</surname><given-names>L.S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1</article-title><source>PLoS Biol</source><year>2007</year><volume>5</volume><fpage>e172</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.0050172</pub-id><pub-id pub-id-type="pmid">17579517</pub-id></citation></ref>
<ref id="b122-ijms-14-02388"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heeman</surname><given-names>B.</given-names></name><name><surname>Van den Haute</surname><given-names>C.</given-names></name><name><surname>Aelvoet</surname><given-names>S.A.</given-names></name><name><surname>Valsecchi</surname><given-names>F.</given-names></name><name><surname>Rodenburg</surname><given-names>R.J.</given-names></name><name><surname>Reumers</surname><given-names>V.</given-names></name><name><surname>Debyser</surname><given-names>Z.</given-names></name><name><surname>Callewaert</surname><given-names>G.</given-names></name><name><surname>Koopman</surname><given-names>W.J.</given-names></name><name><surname>Willems</surname><given-names>P.H.</given-names></name><etal/></person-group><article-title>Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance</article-title><source>J. Cell Sci.</source><year>2011</year><volume>124</volume><fpage>1115</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1242/jcs.078303</pub-id><pub-id pub-id-type="pmid">21385841</pub-id></citation></ref>
<ref id="b123-ijms-14-02388"><label>123</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Shao</surname><given-names>Y.</given-names></name><name><surname>May</surname><given-names>J.</given-names></name><name><surname>Prou</surname><given-names>D.</given-names></name><name><surname>Perier</surname><given-names>C.</given-names></name><name><surname>Dauer</surname><given-names>W.</given-names></name><name><surname>Schon</surname><given-names>E.A.</given-names></name><name><surname>Przedborski</surname><given-names>S.</given-names></name></person-group><article-title>The kinase domain of mitochondrial PINK1 faces the cytoplasm</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>12022</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1073/pnas.0802814105</pub-id><pub-id pub-id-type="pmid">18687899</pub-id></citation></ref>
<ref id="b124-ijms-14-02388"><label>124</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wood-Kaczmar</surname><given-names>A.</given-names></name><name><surname>Gandhi</surname><given-names>S.</given-names></name><name><surname>Yao</surname><given-names>Z.</given-names></name><name><surname>Abramov</surname><given-names>A.Y.</given-names></name><name><surname>Miljan</surname><given-names>E.A.</given-names></name><name><surname>Keen</surname><given-names>G.</given-names></name><name><surname>Stanyer</surname><given-names>L.</given-names></name><name><surname>Hargreaves</surname><given-names>I.</given-names></name><name><surname>Klupsch</surname><given-names>K.</given-names></name><name><surname>Deas</surname><given-names>E.</given-names></name><etal/></person-group><article-title>PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e2455</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0002455</pub-id><pub-id pub-id-type="pmid">18560593</pub-id></citation></ref>
<ref id="b125-ijms-14-02388"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marongiu</surname><given-names>R.</given-names></name><name><surname>Spencer</surname><given-names>B.</given-names></name><name><surname>Crews</surname><given-names>L.</given-names></name><name><surname>Adame</surname><given-names>A.</given-names></name><name><surname>Patrick</surname><given-names>C.</given-names></name><name><surname>Trejo</surname><given-names>M.</given-names></name><name><surname>Dallapiccola</surname><given-names>B.</given-names></name><name><surname>Valente</surname><given-names>E.M.</given-names></name><name><surname>Masliah</surname><given-names>E.</given-names></name></person-group><article-title>Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson’s disease by disturbing calcium flux</article-title><source>J. Neurochem</source><year>2009</year><volume>108</volume><fpage>1561</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.05932.x</pub-id><pub-id pub-id-type="pmid">19166511</pub-id></citation></ref>
<ref id="b126-ijms-14-02388"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimura</surname><given-names>H.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name><name><surname>Kubo</surname><given-names>S.i.</given-names></name><name><surname>Mizuno</surname><given-names>Y.</given-names></name><name><surname>Asakawa</surname><given-names>S.</given-names></name><name><surname>Minoshima</surname><given-names>S.</given-names></name><name><surname>Shimizu</surname><given-names>N.</given-names></name><name><surname>Iwai</surname><given-names>K.</given-names></name><name><surname>Chiba</surname><given-names>T.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase</article-title><source>Nat. Genet</source><year>2000</year><volume>25</volume><fpage>302</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/77060</pub-id><pub-id pub-id-type="pmid">10888878</pub-id></citation></ref>
<ref id="b127-ijms-14-02388"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shimura</surname><given-names>H.</given-names></name><name><surname>Hattori</surname><given-names>N.</given-names></name><name><surname>Kubo</surname><given-names>S.</given-names></name><name><surname>Yoshikawa</surname><given-names>M.</given-names></name><name><surname>Kitada</surname><given-names>T.</given-names></name><name><surname>Matsumine</surname><given-names>H.</given-names></name><name><surname>Asakawa</surname><given-names>S.</given-names></name><name><surname>Minoshima</surname><given-names>S.</given-names></name><name><surname>Yamamura</surname><given-names>Y.</given-names></name><name><surname>Shimizu</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Immunohistochemical and subcellular localization of Parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients</article-title><source>Ann. Neurol.</source><year>1999</year><volume>45</volume><fpage>668</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199905)45:5&lt;668::AID-ANA19&gt;3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">10319893</pub-id></citation></ref>
<ref id="b128-ijms-14-02388"><label>128</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narendra</surname><given-names>D.P.</given-names></name><name><surname>Jin</surname><given-names>S.M.</given-names></name><name><surname>Tanaka</surname><given-names>A.</given-names></name><name><surname>Suen</surname><given-names>D.F.</given-names></name><name><surname>Gautier</surname><given-names>C.A.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Cookson</surname><given-names>M.R.</given-names></name><name><surname>Youle</surname><given-names>R.J.</given-names></name></person-group><article-title>PINK1 is selectively stabilized on impaired mitochondria to activate Parkin</article-title><source>PLoS Biol</source><year>2010</year><volume>8</volume><fpage>e1000298</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000298</pub-id><pub-id pub-id-type="pmid">20126261</pub-id></citation></ref>
<ref id="b129-ijms-14-02388"><label>129</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenner</surname><given-names>P.</given-names></name><name><surname>Olanow</surname><given-names>C.W.</given-names></name></person-group><article-title>Understanding cell death in Parkinson’s disease</article-title><source>Ann. Neurol</source><year>1998</year><volume>44</volume><fpage>S72</fpage><lpage>S84</lpage><pub-id pub-id-type="pmid">9749577</pub-id></citation></ref>
<ref id="b130-ijms-14-02388"><label>130</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pickrell</surname><given-names>A.M.</given-names></name><name><surname>Pinto</surname><given-names>M.</given-names></name><name><surname>Hida</surname><given-names>A.</given-names></name><name><surname>Moraes</surname><given-names>C.T.</given-names></name></person-group><article-title>Striatal dysfunctions associated with mitochondrial DNA damage in dopaminergic neurons in a mouse model of Parkinson’s disease</article-title><source>J. Neurosci</source><year>2011</year><volume>31</volume><fpage>17649</fpage><lpage>17658</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4871-11.2011</pub-id><pub-id pub-id-type="pmid">22131425</pub-id></citation></ref>
<ref id="b131-ijms-14-02388"><label>131</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Grespi</surname><given-names>F.</given-names></name><name><surname>Melino</surname><given-names>G</given-names></name></person-group><article-title>P73 and age-related diseases: Is there any link with Parkinson Disease?</article-title><source>Aging</source><year>2012</year><comment>Available online: <ext-link xlink:href="http://www.impactaging.com/papers/v4/n12/full/100515.html" ext-link-type="uri">http://www.impactaging.com/papers/v4/n12/full/100515.html</ext-link></comment><access-date>(accessed on 5 December 2012)</access-date></citation></ref>
<ref id="b132-ijms-14-02388"><label>132</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imam</surname><given-names>S.Z.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Yamamoto</surname><given-names>A.</given-names></name><name><surname>Valente</surname><given-names>A.J.</given-names></name><name><surname>Ali</surname><given-names>S.F.</given-names></name><name><surname>Bains</surname><given-names>M.</given-names></name><name><surname>Roberts</surname><given-names>J.L.</given-names></name><name><surname>Kahle</surname><given-names>P.J.</given-names></name><name><surname>Clark</surname><given-names>R.A.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name></person-group><article-title>Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: Implications for Parkinson’s disease</article-title><source>J. Neurosci</source><year>2011</year><volume>31</volume><fpage>157</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1833-10.2011</pub-id><pub-id pub-id-type="pmid">21209200</pub-id></citation></ref>
<ref id="b133-ijms-14-02388"><label>133</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>M.</given-names></name><name><surname>Fang</surname><given-names>Y.</given-names></name><name><surname>Bi</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death</article-title><source>J. Neurosci</source><year>2011</year><volume>31</volume><fpage>9611</fpage><lpage>9619</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0035-11.2011</pub-id><pub-id pub-id-type="pmid">21715626</pub-id></citation></ref>
<ref id="b134-ijms-14-02388"><label>134</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Dawson</surname><given-names>V.L.</given-names></name><name><surname>Dawson</surname><given-names>T.M.</given-names></name></person-group><article-title>Oxidative stress and genetics in the pathogenesis of Parkinson’s disease</article-title><source>Neurobiol. Dis</source><year>2000</year><volume>7</volume><fpage>240</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1006/nbdi.2000.0319</pub-id><pub-id pub-id-type="pmid">10964596</pub-id></citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figures</title>
<fig id="f1-ijms-14-02388" position="float">
<label>Figure 1</label>
<caption>
<p>DNA Repair pathways: Homologous Recombination (HR) and Non Homologous Ends Joining (NHEJ) mechanisms are induced by DSBs. Base Excision Repair (BER), Nucleotide Excision Repair (NER) pathways: Global Genome NER (GGNER) and Transcriptional-coupled NER (TCNER) and Mismatch Repair (MMR).</p></caption>
<graphic xlink:href="ijms-14-02388f1.gif"/></fig>
<fig id="f2-ijms-14-02388" position="float">
<label>Figure 2</label>
<caption>
<p>Mitochondria defects in Neurodegenerative Disease: (<bold>A</bold>) Mitochondria are organelles implicated in energy production and endogenous ROS production. They are responsible for more than 90% of the ROS production in the cell. The five proteins of electron transport chain are located in the inner membrane. (<bold>B</bold>) Mitochondrial impairment causes an excessive quantity of ROS/RNS, inducing oxidative stress. The latter is the most frequent event associated with neuronal loss in neurodegenerative diseases.</p></caption>
<graphic xlink:href="ijms-14-02388f2.gif"/></fig>
<fig id="f3-ijms-14-02388" position="float">
<label>Figure 3</label>
<caption>
<p>c-Abl signaling and neuronal diseases: c-Abl plays a central role in several pathways and in oxidative stress response. c-Abl modulates cell death by interacting with p73/p53 transcription factors. c-Abl is also involved in molecular mechanisms underlying several neurodegenerative diseases like PD and AD, promoting Parkin and Tau tyrosine phosphorylation.</p></caption>
<graphic xlink:href="ijms-14-02388f3.gif"/></fig>
<fig id="f4-ijms-14-02388" position="float">
<label>Figure 4</label>
<caption>
<p>Parkinson’s Disease network: PD is a neurodegenerative disease that affects neuronal cells located in the S<italic>ubstantia Nigra</italic>. PD symptoms are caused by cooperative action of various causes leading to neuronal loss of this area. One of the principal causes of PD progression, as indicated by Braak’s theory, consists of progressive formation of α-syn aggregates and their accumulation in SN <italic>pars compacta</italic>. The figure illustrates also the importance of mitochondria, which are responsible for ATP generation and oxidative stress. PINK1 is localized in the inner membrane of mitochondria (see text). However, under pathological conditions, PINK1 moves to the outer membrane and recruits Parkin. This event may induce autophagy by an ubiquitin-mediated mechanism. Parkin can also be phosphorylated by c-Abl increasing oxidative stress and promoting neuronal cell death.</p></caption>
<graphic xlink:href="ijms-14-02388f4.gif"/></fig></sec></back></article>
